[{"studyInfo": {"title": "Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia", "institution": "Sumitomo Pharma America, Inc.", "dates": {"start": null, "completion": "2011-10"}, "summary": null}, "participants": [{"groupName": "Eszopiclone Overall", "dosage": "2mg Eszopiclone", "medicationName": "Eszopiclone", "size": 303, "description": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)"}], "outcomes": [{"metric_name": "Overall Incidence of Adverse Events", "data": [{"label": "Serious TEAE", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 4.0}]}, {"label": "Discontinued study due to TEAE", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 34.0}]}, {"label": "Subjects with at least 1 TEAE", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 212.0}]}, {"label": "Fatal TEAE", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.0}]}, {"label": "Severe TEAE", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 10.0}]}, {"label": "Potentially-related TEAE", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 138.0}]}], "yAxis": {"label": "Value", "unit": "participants"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Overall Incidence of Skin Reactions: Number of Events", "data": [{"label": "Overall Incidence of Skin Reactions: Number of Events", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 17.0}]}], "yAxis": {"label": "Value", "unit": "Events"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Overall Incidence of Skin Reactions: Number of Participant Affected", "data": [{"label": "Overall Incidence of Skin Reactions: Number of Participant Affected", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 13.0}]}], "yAxis": {"label": "Value", "unit": "participants"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses", "data": [{"label": "Aborted Attempt", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.0}]}, {"label": "Any Suicidality", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 4.0}]}, {"label": "Active Suicidal Ideation w/ Some Intent to Act", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Preparatory Acts or Behavior", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Non-specific Active Suicidal Thoughts", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 3.0}]}, {"label": "Any Suicidal Behavior", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.0}]}, {"label": "Any Suicidal Ideation", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 4.0}]}, {"label": "Active Suicidal Ideation without Intent to Act", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Actual Attempt", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Completed Suicide", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Wish to be Dead", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Interrupted Attempt", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.0}]}, {"label": "Active Suicidal Ideation w/ Specific Plan", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.0}]}], "yAxis": {"label": "Value", "unit": "Subjects"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)", "data": [{"label": "Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -22.7}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)", "data": [{"label": "Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -0.8}]}], "yAxis": {"label": "Value", "unit": "Number of Awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12", "data": [{"label": "Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.1}]}], "yAxis": {"label": "Value", "unit": "score"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12", "data": [{"label": "From Child", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 2.6}]}, {"label": "From Parent", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 2.6}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline at Month 12 in Subjective Sleep Latency (SL)", "data": [{"label": "Change From Baseline at Month 12 in Subjective Sleep Latency (SL)", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -18.1}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline in Child Behavior Checklist (CBCL)", "data": [{"label": "Externalizing problems standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.29}]}, {"label": "Internalizing problems standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.19}]}, {"label": "Social scale standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.94}]}, {"label": "Activities scale standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.04}]}, {"label": "Total competence standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 1.02}]}, {"label": "Total problems standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.19}]}, {"label": "School scale standardized score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.02}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).", "data": [{"label": "Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 45.3}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12", "data": [{"label": "Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -3.9}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline in Conners' Continuous Performance Test II (CCPT II)", "data": [{"label": "Hit RT Std Error Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 8.747}]}, {"label": "Hit SE Block Change Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -2.919}]}, {"label": "Responsive Style (beta) Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -3.614}]}, {"label": "Perseverations % Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 4.807}]}, {"label": "Hit RT Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 5.933}]}, {"label": "Hit RT Block Change Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 0.213}]}, {"label": "Hit RT ISI Change Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 8.07}]}, {"label": "Omissions % Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 10.285}]}, {"label": "Hit SE ISI Change Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 8.27}]}, {"label": "Variability Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 8.781}]}, {"label": "Confidence Index", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 8.471}]}, {"label": "Commissions % Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -5.98}]}, {"label": "Detectability (d') Percentile", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -3.614}]}], "yAxis": {"label": "Value", "unit": "percentage of score"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change From Baseline in Pediatric Quality of Life Scale", "data": [{"label": "Psychosocial Summary Score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": 2.14}]}, {"label": "Physical Summary Score", "values": [{"group": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "value": -1.31}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Headache (16.88%), Dysgeusia (10.91%), Dizziness (7.79%).", "common": [{"event": "Headache", "percentage": 16.88}, {"event": "Dysgeusia", "percentage": 10.91}, {"event": "Dizziness", "percentage": 7.79}, {"event": "Nasopharyngitis", "percentage": 5.19}, {"event": "Abdominal Pain Upper", "percentage": 4.94}, {"event": "Cough", "percentage": 4.16}, {"event": "Pyrexia", "percentage": 4.16}, {"event": "Somnolence", "percentage": 3.9}, {"event": "Vomiting", "percentage": 3.9}, {"event": "Diarrhoea", "percentage": 3.38}, {"event": "Nausea", "percentage": 3.38}, {"event": "Oropharyngeal pain", "percentage": 3.38}, {"event": "Upper respiratory infection", "percentage": 3.12}, {"event": "Nasal congestion", "percentage": 3.12}, {"event": "Sinusitis", "percentage": 2.86}, {"event": "Influenza", "percentage": 2.6}, {"event": "Insomnia", "percentage": 2.6}, {"event": "Toothache", "percentage": 2.34}, {"event": "Pharyngitis streptococcal", "percentage": 2.08}, {"event": "Abdominal discomfort", "percentage": 1.82}, {"event": "Hallucination, visual", "percentage": 1.82}, {"event": "Urinary tract infection", "percentage": 1.56}, {"event": "Influenza like illness", "percentage": 1.56}, {"event": "Contusion", "percentage": 1.56}, {"event": "Drowning", "percentage": 0.26}, {"event": "Viral Infection", "percentage": 0.26}, {"event": "Upper limb fracture", "percentage": 0.26}, {"event": "Delirium", "percentage": 0.26}]}}, {"studyInfo": {"title": "Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia", "institution": "Yale University", "dates": {"start": null, "completion": "2011-04"}, "summary": null}, "participants": [{"groupName": "Eszopiclone Group", "dosage": "Eszopiclone 2mg for 1 week, then 3mg for remaining weeks", "medicationName": "Eszopiclone", "size": 9, "description": "Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks."}, {"groupName": "Placebo Group", "dosage": "Placebo", "medicationName": "placebo", "size": 9, "description": "Participants assigned to this arm will receive placebo (an inactive substance or a 'sugar pill') to be taken each night for all weeks of the study."}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 18, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Change in Insomnia Severity Index From Baseline.", "data": [{"label": "Change in Insomnia Severity Index From Baseline.", "values": [{"group": "Eszopiclone Group", "value": -10.7}, {"group": "Placebo Group", "value": -6.9}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Sedation/drowsiness (20.55%), Dry Mouth (12.33%), Headache (5.48%).", "common": [{"event": "Sedation/drowsiness", "percentage": 20.55}, {"event": "Dry Mouth", "percentage": 12.33}, {"event": "Headache", "percentage": 5.48}, {"event": "Other", "percentage": 5.48}, {"event": "Irritability", "percentage": 4.11}, {"event": "Malaise", "percentage": 4.11}, {"event": "Dizziness/faintness", "percentage": 4.11}, {"event": "Nasal Congestion", "percentage": 4.11}, {"event": "Nausea/Vomiting", "percentage": 4.11}, {"event": "Unpleasant Taste", "percentage": 2.74}, {"event": "Memory Problems", "percentage": 2.74}, {"event": "Increased Salivation", "percentage": 2.74}, {"event": "Appetite Increase", "percentage": 2.74}, {"event": "Weight Loss", "percentage": 2.74}, {"event": "Fatigue", "percentage": 1.37}, {"event": "Fatigue/Weakness", "percentage": 1.37}, {"event": "Excitement/nervousness", "percentage": 1.37}, {"event": "Delusions", "percentage": 1.37}, {"event": "Vision Blurred", "percentage": 1.37}, {"event": "Tremor", "percentage": 1.37}, {"event": "Ataxia", "percentage": 1.37}, {"event": "Hyperventilation", "percentage": 1.37}, {"event": "Stomach/ abdominal discomfort", "percentage": 1.37}, {"event": "Constipation", "percentage": 1.37}, {"event": "Diarrhea", "percentage": 1.37}, {"event": "Urination Problems", "percentage": 1.37}, {"event": "Libido Decrease", "percentage": 1.37}, {"event": "Orgasmic Dysfunction", "percentage": 1.37}, {"event": "Sweating", "percentage": 1.37}, {"event": "Appetite Decrease", "percentage": 1.37}]}}, {"studyInfo": {"title": "Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone", "institution": "Rutgers, The State University of New Jersey", "dates": {"start": null, "completion": "2009-06"}, "summary": null}, "participants": [{"groupName": "Eszopiclone", "dosage": "3mg of eszopiclone each night at bedtime", "medicationName": "Eszopiclone", "size": 13, "description": "Those under 65 years old received 3mg of eszopiclone (or randomized to matching placebo) each night at bedtime."}, {"groupName": "Placebo", "dosage": "Placebo each night at bedtime", "medicationName": "Placebo", "size": 11, "description": "Those randomly assigned to matching placebo took their dose each night at bedtime."}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 24, "description": "Total of all reporting groups."}], "outcomes": [{"metric_name": "TST", "data": [{"label": "TST", "values": [{"group": "Placebo", "value": 6.0}, {"group": "Eszopiclone", "value": 5.7}]}], "yAxis": {"label": "Value", "unit": "hours"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "WASO", "data": [{"label": "WASO", "values": [{"group": "Eszopiclone", "value": 17.0}, {"group": "Placebo", "value": 46.0}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were daytime fatigue (42.86%), sedation (28.57%), dizziness (14.29%).", "common": [{"event": "daytime fatigue", "percentage": 42.86}, {"event": "sedation", "percentage": 28.57}, {"event": "dizziness", "percentage": 14.29}, {"event": "increase Parkinson's related rigidity", "percentage": 14.29}]}}, {"studyInfo": {"title": "Eszopiclone in the Treatment of Insomnia and Fibromyalgia", "institution": "Rutgers, The State University of New Jersey", "dates": {"start": null, "completion": "2009-03"}, "summary": null}, "participants": [{"groupName": "Eszopiclone", "dosage": "Eszopiclone: 3mg qpm for 12 weeks", "medicationName": "Eszopiclone", "size": 19, "description": "Total of all reporting groups"}, {"groupName": "Placebo", "dosage": "placebo: 1 pill qpm for 12 weeks", "medicationName": "Placebo", "size": 17, "description": "Total of all reporting groups"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 36, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Change in Total Sleep Time (TST) as Recorded in Patient Diaries", "data": [{"label": "Change in Total Sleep Time (TST) as Recorded in Patient Diaries", "values": [{"group": "Eszopiclone", "value": 68.72}, {"group": "Placebo", "value": 13.47}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "No adverse events reported.", "common": []}}, {"studyInfo": {"title": "A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)", "institution": "Eisai Inc.", "dates": {"start": null, "completion": "2010-02"}, "summary": null}, "participants": [{"groupName": "Group A: Eszopiclone One 3 mg Tab First, Then Three 1mg Tabs", "dosage": "Eszopiclone 3 mg, Morning, Fasting", "medicationName": "Eszopiclone", "size": 0, "description": "Participants received Eszopiclone one 3 mg tablets administered orally with water in the morning after fasting for 10 or more hours for 3 days in Period I. After a washout period of 5 or more days, participants were crossed over and received Eszopiclone three 1 mg tablets with water in the morning after fasting for 10 or more hours for 3 days in Period II. At least a 5 day period passed before post treatment examinations."}, {"groupName": "Group B: Eszopiclone Three 1 mg Tabs First, Then One 3 mg Tab", "dosage": "Eszopiclone 1 mg, Morning, Fasting", "medicationName": "Eszopiclone", "size": 0, "description": "Participants received Eszopiclone three 1 mg tablets administered orally with water in the morning after fasting for 10 or more hours for 3 days in Period I. After a washout period of 5 or more days, participants were crossed over and received Eszopiclone one 3 mg tablets with water in the morning after fasting for 10 or more hours for 3 days in Period II.\n\nAfter Period II there was at least a 5 day washout period. Certain participants from Group B only proceeded to Period III where they received Eszopiclone one 3 mg tablet taken orally with water, 30 minutes after the start of breakfast for 3 days. At least a 5 day period passed before post treatment examinations."}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 0, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Pharmacokinetic Parameter (Bioequivalence): Maximal Drug Concentration (Cmax)", "data": [{"label": "Pharmacokinetic Parameter (Bioequivalence): Maximal Drug Concentration (Cmax)", "values": [{"group": "Eszopiclone One 3 mg Tablet", "value": 40.8}, {"group": "Eszopiclone Three 1 mg Tablets", "value": 40.21}]}], "yAxis": {"label": "Value", "unit": "ng/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Pharmacokinetic Parameter (Bioequivalence): Area Under the Plasma Concentration- Time Curve From Time 0 to Time 24 Hours (AUC[0-24])", "data": [{"label": "Pharmacokinetic Parameter (Bioequivalence): Area Under the Plasma Concentration- Time Curve From Time 0 to Time 24 Hours (AUC[0-24])", "values": [{"group": "Eszopiclone One 3 mg Tablet", "value": 212.59}, {"group": "Eszopiclone Three 1 mg Tablets", "value": 210.03}]}], "yAxis": {"label": "Value", "unit": "ng*h/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Pharmacokinetic Parameter (Food Effect): Maximal Drug Concentration (Cmax)", "data": [{"label": "Fasted Cmax", "values": [{"group": "Eszopiclone One 3 mg Tablet", "value": 37.59}]}, {"label": "Fed Cmax", "values": [{"group": "Eszopiclone One 3 mg Tablet", "value": 26.56}]}], "yAxis": {"label": "Value", "unit": "ng/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Pharmacokinetic Parameter (Food Effect): Area Under the Plasma Concentration- Time Curve From Time 0 to Time 24 Hours (AUC[0-24])", "data": [{"label": "Fed AUC [0-24]", "values": [{"group": "Eszopiclone One 3 mg Tablet", "value": 194.53}]}, {"label": "Fasted AUC [0-24]", "values": [{"group": "Eszopiclone One 3 mg Tablet", "value": 199.17}]}], "yAxis": {"label": "Value", "unit": "ng*hr/mL"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Dysgeusia (71.43%), Urticaria (14.29%), Pyrexia (14.29%).", "common": [{"event": "Dysgeusia", "percentage": 71.43}, {"event": "Urticaria", "percentage": 14.29}, {"event": "Pyrexia", "percentage": 14.29}]}}, {"studyInfo": {"title": "A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia", "institution": "Sumitomo Pharma America, Inc.", "dates": {"start": null, "completion": "2008-02"}, "summary": null}, "participants": [{"groupName": "Placebo", "dosage": "Placebo", "medicationName": "Placebo", "size": 0, "description": "Placebo tablets"}, {"groupName": "Eszopiclone", "dosage": "Eszopiclone 2 mg tablets", "medicationName": "Eszopiclone", "size": 0, "description": "Eszopiclone 2 mg tablets"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 388, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Mean Subject-reported Total Sleep Time in Minutes at Various Study Time Points.", "data": [{"label": "Week 12 (n=192,193)", "values": [{"group": "Placebo", "value": 334.69}, {"group": "Eszopiclone", "value": 367.75}]}, {"label": "Week 0 (n=192,191)", "values": [{"group": "Placebo", "value": 294.03}, {"group": "Eszopiclone", "value": 297.86}]}, {"label": "Week 9 (n=192,193)", "values": [{"group": "Placebo", "value": 332.47}, {"group": "Eszopiclone", "value": 365.8}]}, {"label": "Week 3 (n=192,192)", "values": [{"group": "Placebo", "value": 314.53}, {"group": "Eszopiclone", "value": 347.37}]}, {"label": "Week 14 (n=192,193)", "values": [{"group": "Placebo", "value": 336.55}, {"group": "Eszopiclone", "value": 347.12}]}, {"label": "Week 16 (n=192,193)", "values": [{"group": "Placebo", "value": 331.29}, {"group": "Eszopiclone", "value": 344.2}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=192,193)", "values": [{"group": "Placebo", "value": 326.98}, {"group": "Eszopiclone", "value": 360.08}]}, {"label": "Week 6 (n=192,193)", "values": [{"group": "Placebo", "value": 326.25}, {"group": "Eszopiclone", "value": 358.72}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Total Sleep Time at Various Study Time Points.", "data": [{"label": "Week 6 (n=191,191)", "values": [{"group": "Eszopiclone", "value": 61.91}, {"group": "Placebo", "value": 32.47}]}, {"label": "Week 3 (n=191,190)", "values": [{"group": "Eszopiclone", "value": 51.02}, {"group": "Placebo", "value": 20.65}]}, {"label": "Week 16 (n=191,191)", "values": [{"group": "Eszopiclone", "value": 47.17}, {"group": "Placebo", "value": 37.43}]}, {"label": "Week 12 (n=191,191)", "values": [{"group": "Eszopiclone", "value": 70.97}, {"group": "Placebo", "value": 40.86}]}, {"label": "Week 9 (n=191,191)", "values": [{"group": "Eszopiclone", "value": 69.0}, {"group": "Placebo", "value": 38.73}]}, {"label": "Week 14 (n=191,191)", "values": [{"group": "Eszopiclone", "value": 50.12}, {"group": "Placebo", "value": 42.78}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period.", "data": [{"label": "Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period.", "values": [{"group": "Placebo", "value": 33.18}, {"group": "Eszopiclone", "value": 63.24}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Sleep Latency (SL) Averaged Over the 12 Week Double Blind Period.", "data": [{"label": "Mean Change From Baseline in Subject-reported Sleep Latency (SL) Averaged Over the 12 Week Double Blind Period.", "values": [{"group": "Placebo", "value": -19.92}, {"group": "Eszopiclone", "value": -24.62}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Sleep Latency at Various Study Time Points", "data": [{"label": "Week 6 (n=191,191)", "values": [{"group": "Eszopiclone", "value": -24.13}, {"group": "Placebo", "value": -19.69}]}, {"label": "Week 3 (n=191,190)", "values": [{"group": "Eszopiclone", "value": -21.89}, {"group": "Placebo", "value": -13.34}]}, {"label": "Week 16 (n=191,191)", "values": [{"group": "Eszopiclone", "value": -18.73}, {"group": "Placebo", "value": -24.61}]}, {"label": "Week 12 (n=191,191)", "values": [{"group": "Eszopiclone", "value": -28.35}, {"group": "Placebo", "value": -23.54}]}, {"label": "Week 9 (n=191,191)", "values": [{"group": "Eszopiclone", "value": -24.21}, {"group": "Placebo", "value": -23.02}]}, {"label": "Week 14 (n=191,191)", "values": [{"group": "Eszopiclone", "value": -17.0}, {"group": "Placebo", "value": -25.08}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Sleep Latency Reported at Various Study Time Points.", "data": [{"label": "Week 12 (n=192,193)", "values": [{"group": "Placebo", "value": 58.69}, {"group": "Eszopiclone", "value": 47.66}]}, {"label": "Week 0 (n=192,191)", "values": [{"group": "Placebo", "value": 82.17}, {"group": "Eszopiclone", "value": 75.68}]}, {"label": "Week 9 (n=192,193)", "values": [{"group": "Placebo", "value": 59.23}, {"group": "Eszopiclone", "value": 51.75}]}, {"label": "Week 3 (n=192,192)", "values": [{"group": "Placebo", "value": 68.8}, {"group": "Eszopiclone", "value": 54.69}]}, {"label": "Week 14 (n=192,193)", "values": [{"group": "Placebo", "value": 57.23}, {"group": "Eszopiclone", "value": 58.89}]}, {"label": "Week 16 (n=192,193)", "values": [{"group": "Placebo", "value": 57.62}, {"group": "Eszopiclone", "value": 57.17}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=192,193)", "values": [{"group": "Placebo", "value": 62.32}, {"group": "Eszopiclone", "value": 51.51}]}, {"label": "Week 6 (n=192,193)", "values": [{"group": "Placebo", "value": 62.57}, {"group": "Eszopiclone", "value": 52.11}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) Averaged Over the 12 Week Double-blind Study Period.", "data": [{"label": "Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) Averaged Over the 12 Week Double-blind Study Period.", "values": [{"group": "Placebo", "value": -14.75}, {"group": "Eszopiclone", "value": -36.4}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points.", "data": [{"label": "Week 12 (n=189,191)", "values": [{"group": "Placebo", "value": -19.13}, {"group": "Eszopiclone", "value": -39.61}]}, {"label": "Week 16 (n=189,191)", "values": [{"group": "Placebo", "value": -20.18}, {"group": "Eszopiclone", "value": -31.13}]}, {"label": "Week 14 (n=189,191)", "values": [{"group": "Placebo", "value": -22.72}, {"group": "Eszopiclone", "value": -32.27}]}, {"label": "Week 3 (n=188,190)", "values": [{"group": "Placebo", "value": -8.55}, {"group": "Eszopiclone", "value": -29.26}]}, {"label": "Week 6 (n=189,191)", "values": [{"group": "Placebo", "value": -13.46}, {"group": "Eszopiclone", "value": -36.57}]}, {"label": "Week 9 (n=189,191)", "values": [{"group": "Placebo", "value": -17.67}, {"group": "Eszopiclone", "value": -40.32}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points", "data": [{"label": "Week 12 (n=192,193)", "values": [{"group": "Placebo", "value": 72.02}, {"group": "Eszopiclone", "value": 53.45}]}, {"label": "Week 9 (n=192,193)", "values": [{"group": "Placebo", "value": 73.33}, {"group": "Eszopiclone", "value": 52.75}]}, {"label": "Week 14 (n=192,193)", "values": [{"group": "Placebo", "value": 68.39}, {"group": "Eszopiclone", "value": 60.71}]}, {"label": "Week 16 (n=192,193)", "values": [{"group": "Placebo", "value": 71.27}, {"group": "Eszopiclone", "value": 61.84}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=192,193)", "values": [{"group": "Placebo", "value": 76.59}, {"group": "Eszopiclone", "value": 56.68}]}, {"label": "Week 3 (n=190,192)", "values": [{"group": "Placebo", "value": 83.17}, {"group": "Eszopiclone", "value": 64.33}]}, {"label": "Week 0 (n=190,191)", "values": [{"group": "Placebo", "value": 90.86}, {"group": "Eszopiclone", "value": 92.66}]}, {"label": "Week 6 (n=192,193)", "values": [{"group": "Placebo", "value": 77.86}, {"group": "Eszopiclone", "value": 56.49}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Number of Awakenings Averaged Over the 12 Week Double Blind Study Period.", "data": [{"label": "Mean Change From Baseline in Subject-reported Number of Awakenings Averaged Over the 12 Week Double Blind Study Period.", "values": [{"group": "Placebo", "value": -0.27}, {"group": "Eszopiclone", "value": -0.56}]}], "yAxis": {"label": "Value", "unit": "number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in the Number of Subject-reported Awakenings at Various Study Time Points.", "data": [{"label": "Week 12 (n=189,191)", "values": [{"group": "Placebo", "value": -0.35}, {"group": "Eszopiclone", "value": -0.65}]}, {"label": "Week 16 (n=189,191)", "values": [{"group": "Placebo", "value": -0.35}, {"group": "Eszopiclone", "value": -0.44}]}, {"label": "Week 14 (n=189,191)", "values": [{"group": "Placebo", "value": -0.38}, {"group": "Eszopiclone", "value": -0.46}]}, {"label": "Week 3 (n=188,190)", "values": [{"group": "Placebo", "value": -0.16}, {"group": "Eszopiclone", "value": -0.46}]}, {"label": "Week 6 (n=189,191)", "values": [{"group": "Placebo", "value": -0.24}, {"group": "Eszopiclone", "value": -0.56}]}, {"label": "Week 9 (n=189,191)", "values": [{"group": "Placebo", "value": -0.33}, {"group": "Eszopiclone", "value": -0.57}]}], "yAxis": {"label": "Value", "unit": "number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Depth of Sleep at Various Study Time Points", "data": [{"label": "Week 6 (n=189, 191)", "values": [{"group": "Eszopiclone", "value": 1.3}, {"group": "Placebo", "value": 0.62}]}, {"label": "Week 16 (n=189,191)", "values": [{"group": "Eszopiclone", "value": 1.15}, {"group": "Placebo", "value": 0.88}]}, {"label": "Week 12 (n=189, 191)", "values": [{"group": "Eszopiclone", "value": 1.49}, {"group": "Placebo", "value": 0.93}]}, {"label": "Week 14 (n=189,191)", "values": [{"group": "Eszopiclone", "value": 1.23}, {"group": "Placebo", "value": 1.0}]}, {"label": "Week 3 (n=188, 190)", "values": [{"group": "Eszopiclone", "value": 1.07}, {"group": "Placebo", "value": 0.4}]}, {"label": "Week 9 (n=189, 191)", "values": [{"group": "Eszopiclone", "value": 1.46}, {"group": "Placebo", "value": 0.82}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Number of Awakenings (Subject-reported) at Various Study Time Points", "data": [{"label": "Week 12 (n=192,193)", "values": [{"group": "Placebo", "value": 1.61}, {"group": "Eszopiclone", "value": 1.46}]}, {"label": "Week 9 (n=192,193)", "values": [{"group": "Placebo", "value": 1.62}, {"group": "Eszopiclone", "value": 1.54}]}, {"label": "Week 14 (n=192,193)", "values": [{"group": "Placebo", "value": 1.58}, {"group": "Eszopiclone", "value": 1.65}]}, {"label": "Week 16 (n=192,193)", "values": [{"group": "Placebo", "value": 1.61}, {"group": "Eszopiclone", "value": 1.66}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=192,193)", "values": [{"group": "Placebo", "value": 1.68}, {"group": "Eszopiclone", "value": 1.55}]}, {"label": "Week 3 (n=190,192)", "values": [{"group": "Placebo", "value": 1.78}, {"group": "Eszopiclone", "value": 1.66}]}, {"label": "Week 0 (n=190,191)", "values": [{"group": "Placebo", "value": 1.95}, {"group": "Eszopiclone", "value": 2.1}]}, {"label": "Week 6 (n=192,193)", "values": [{"group": "Placebo", "value": 1.72}, {"group": "Eszopiclone", "value": 1.55}]}], "yAxis": {"label": "Value", "unit": "number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Quality of Sleep Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Subject-reported Quality of Sleep Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 0.68}, {"group": "Eszopiclone", "value": 1.39}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Quality of Sleep at Various Study Time Points.", "data": [{"label": "Week 12 (n=189,191)", "values": [{"group": "Placebo", "value": 0.92}, {"group": "Eszopiclone", "value": 1.57}]}, {"label": "Week 14 (n=189,191)", "values": [{"group": "Placebo", "value": 1.02}, {"group": "Eszopiclone", "value": 1.26}]}, {"label": "Week 3 (n=188,190)", "values": [{"group": "Placebo", "value": 0.37}, {"group": "Eszopiclone", "value": 1.12}]}, {"label": "Week 16 (n=189, 191)", "values": [{"group": "Placebo", "value": 0.88}, {"group": "Eszopiclone", "value": 1.22}]}, {"label": "Week 6 (n=189,191)", "values": [{"group": "Placebo", "value": 0.62}, {"group": "Eszopiclone", "value": 1.35}]}, {"label": "Week 9 (n=189,191)", "values": [{"group": "Placebo", "value": 0.81}, {"group": "Eszopiclone", "value": 1.52}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Ratings of Subject-reported Quality of Sleep at Various Study Time Points", "data": [{"label": "Week 12 (n=192,193)", "values": [{"group": "Placebo", "value": 5.78}, {"group": "Eszopiclone", "value": 6.22}]}, {"label": "Week 9 (n=192,193)", "values": [{"group": "Placebo", "value": 5.67}, {"group": "Eszopiclone", "value": 6.17}]}, {"label": "Week 14 (n=192,193)", "values": [{"group": "Placebo", "value": 5.88}, {"group": "Eszopiclone", "value": 5.91}]}, {"label": "Week 16 (n=192,193)", "values": [{"group": "Placebo", "value": 5.73}, {"group": "Eszopiclone", "value": 5.88}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=192, 193)", "values": [{"group": "Placebo", "value": 5.54}, {"group": "Eszopiclone", "value": 6.04}]}, {"label": "Week 0 (n=190,191)", "values": [{"group": "Placebo", "value": 4.84}, {"group": "Eszopiclone", "value": 4.68}]}, {"label": "Week 3 (n=190,190)", "values": [{"group": "Placebo", "value": 5.22}, {"group": "Eszopiclone", "value": 5.77}]}, {"label": "Week 6 (n=192,193)", "values": [{"group": "Placebo", "value": 5.48}, {"group": "Eszopiclone", "value": 6.01}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Depth of Sleep for the Average Reported During the Double-blind Period.", "data": [{"label": "Mean Change From Baseline in Subject-Reported Depth of Sleep for the Average Reported During the Double-blind Period.", "values": [{"group": "Placebo", "value": 0.69}, {"group": "Eszopiclone", "value": 1.33}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Depth of Sleep at Various Study Time Points", "data": [{"label": "Week 12 (n=192, 193)", "values": [{"group": "Placebo", "value": 5.82}, {"group": "Eszopiclone", "value": 6.18}]}, {"label": "Week 9 (n=192,193)", "values": [{"group": "Placebo", "value": 5.71}, {"group": "Eszopiclone", "value": 6.15}]}, {"label": "Week 14 (n=192,193)", "values": [{"group": "Placebo", "value": 5.89}, {"group": "Eszopiclone", "value": 5.92}]}, {"label": "Week 16 (n=192,193)", "values": [{"group": "Placebo", "value": 5.76}, {"group": "Eszopiclone", "value": 5.84}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=192,193)", "values": [{"group": "Placebo", "value": 5.58}, {"group": "Eszopiclone", "value": 6.02}]}, {"label": "Week 3 (n=190,192)", "values": [{"group": "Placebo", "value": 5.29}, {"group": "Eszopiclone", "value": 5.76}]}, {"label": "Week 0 (n=190,191)", "values": [{"group": "Placebo", "value": 4.87}, {"group": "Eszopiclone", "value": 4.72}]}, {"label": "Week 6 (n=192,193)", "values": [{"group": "Placebo", "value": 5.51}, {"group": "Eszopiclone", "value": 6.0}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change in Subject-reported Daytime Alertness Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change in Subject-reported Daytime Alertness Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 0.61}, {"group": "Eszopiclone", "value": 1.02}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Daytime Alertness at Various Study Time Points", "data": [{"label": "Week 6 (n=189,192)", "values": [{"group": "Placebo", "value": 0.55}, {"group": "Eszopiclone", "value": 0.99}]}, {"label": "Week 16 (n=189,192)", "values": [{"group": "Placebo", "value": 0.78}, {"group": "Eszopiclone", "value": 0.97}]}, {"label": "Week 3 (n=189,191)", "values": [{"group": "Placebo", "value": 0.39}, {"group": "Eszopiclone", "value": 0.76}]}, {"label": "Week 14 (n=189,192)", "values": [{"group": "Placebo", "value": 0.85}, {"group": "Eszopiclone", "value": 1.05}]}, {"label": "Week 9 (n=189,192)", "values": [{"group": "Placebo", "value": 0.72}, {"group": "Eszopiclone", "value": 1.1}]}, {"label": "Week 12 (n=189,192)", "values": [{"group": "Placebo", "value": 0.78}, {"group": "Eszopiclone", "value": 1.21}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Daytime Alertness at Various Study Time Points.", "data": [{"label": "Week 3 (n=190,191)", "values": [{"group": "Placebo", "value": 5.74}, {"group": "Eszopiclone", "value": 6.18}]}, {"label": "Week 16 (n=190,192)", "values": [{"group": "Placebo", "value": 6.13}, {"group": "Eszopiclone", "value": 6.39}]}, {"label": "Week 6 (n=190,192)", "values": [{"group": "Placebo", "value": 5.89}, {"group": "Eszopiclone", "value": 6.41}]}, {"label": "Week 9 (n=190,192)", "values": [{"group": "Placebo", "value": 6.06}, {"group": "Eszopiclone", "value": 6.52}]}, {"label": "Week 14 (n=190,192)", "values": [{"group": "Placebo", "value": 6.19}, {"group": "Eszopiclone", "value": 6.47}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=190,192)", "values": [{"group": "Placebo", "value": 5.95}, {"group": "Eszopiclone", "value": 6.44}]}, {"label": "Week 12 (n=190,192)", "values": [{"group": "Placebo", "value": 6.13}, {"group": "Eszopiclone", "value": 6.64}]}, {"label": "Week 0 (n=192,193)", "values": [{"group": "Placebo", "value": 5.34}, {"group": "Eszopiclone", "value": 5.42}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Ability to Function Averaged Over the 12 Week Double Blind Period", "data": [{"label": "Mean Change From Baseline in Subject-Reported Ability to Function Averaged Over the 12 Week Double Blind Period", "values": [{"group": "Placebo", "value": 0.53}, {"group": "Eszopiclone", "value": 0.91}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Ability to Function at Various Study Time Points", "data": [{"label": "Week 6 (n=189,192)", "values": [{"group": "Placebo", "value": 0.46}, {"group": "Eszopiclone", "value": 0.87}]}, {"label": "Week 16 (n=189,192)", "values": [{"group": "Placebo", "value": 0.69}, {"group": "Eszopiclone", "value": 0.87}]}, {"label": "Week 3 (n=189,191)", "values": [{"group": "Placebo", "value": 0.36}, {"group": "Eszopiclone", "value": 0.69}]}, {"label": "Week 14 (n=189,192)", "values": [{"group": "Placebo", "value": 0.75}, {"group": "Eszopiclone", "value": 0.96}]}, {"label": "Week 9 (n=189,192)", "values": [{"group": "Placebo", "value": 0.62}, {"group": "Eszopiclone", "value": 0.98}]}, {"label": "Week 12 (n=189,192)", "values": [{"group": "Placebo", "value": 0.69}, {"group": "Eszopiclone", "value": 1.08}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Ability to Function at Various Study Time Points", "data": [{"label": "Week 3 (n=190,191)", "values": [{"group": "Placebo", "value": 5.98}, {"group": "Eszopiclone", "value": 6.38}]}, {"label": "Week 16 (n=190,192)", "values": [{"group": "Placebo", "value": 6.31}, {"group": "Eszopiclone", "value": 6.57}]}, {"label": "Week 6 (n=190,192)", "values": [{"group": "Placebo", "value": 6.09}, {"group": "Eszopiclone", "value": 6.57}]}, {"label": "Week 9 (n=190,192)", "values": [{"group": "Placebo", "value": 6.24}, {"group": "Eszopiclone", "value": 6.69}]}, {"label": "Week 14 (n=190,192)", "values": [{"group": "Placebo", "value": 6.38}, {"group": "Eszopiclone", "value": 6.66}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=190,192)", "values": [{"group": "Placebo", "value": 6.16}, {"group": "Eszopiclone", "value": 6.61}]}, {"label": "Week 12 (n=190,192)", "values": [{"group": "Placebo", "value": 6.32}, {"group": "Eszopiclone", "value": 6.79}]}, {"label": "Week 0 (n=192,193)", "values": [{"group": "Placebo", "value": 5.62}, {"group": "Eszopiclone", "value": 5.69}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Ability to Concentrate Averaged Over the 12 Week Double Blind Study Period.", "data": [{"label": "Mean Change From Baseline in Subject-reported Ability to Concentrate Averaged Over the 12 Week Double Blind Study Period.", "values": [{"group": "Placebo", "value": 0.5}, {"group": "Eszopiclone", "value": 0.96}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Ability to Concentrate at Various Study Time Points.", "data": [{"label": "Week 6 (n=189,192)", "values": [{"group": "Placebo", "value": 0.43}, {"group": "Eszopiclone", "value": 0.93}]}, {"label": "Week 16 (n=189,192)", "values": [{"group": "Placebo", "value": 0.66}, {"group": "Eszopiclone", "value": 0.93}]}, {"label": "Week 3 (n=189,191)", "values": [{"group": "Placebo", "value": 0.32}, {"group": "Eszopiclone", "value": 0.73}]}, {"label": "Week 14 (n=189,192)", "values": [{"group": "Placebo", "value": 0.72}, {"group": "Eszopiclone", "value": 1.0}]}, {"label": "Week 9 (n=189,192)", "values": [{"group": "Placebo", "value": 0.6}, {"group": "Eszopiclone", "value": 1.03}]}, {"label": "Week 12 (n=189,192)", "values": [{"group": "Placebo", "value": 0.66}, {"group": "Eszopiclone", "value": 1.14}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Ability to Concentrate at Various Study Time Points", "data": [{"label": "Week 3 (n=190,191)", "values": [{"group": "Placebo", "value": 5.99}, {"group": "Eszopiclone", "value": 6.37}]}, {"label": "Week 16 (n=190,192)", "values": [{"group": "Placebo", "value": 6.33}, {"group": "Eszopiclone", "value": 6.56}]}, {"label": "Week 6 (n=190,192)", "values": [{"group": "Placebo", "value": 6.1}, {"group": "Eszopiclone", "value": 6.57}]}, {"label": "Week 9 (n=190,192)", "values": [{"group": "Placebo", "value": 6.27}, {"group": "Eszopiclone", "value": 6.67}]}, {"label": "Week 14 (n=190,192)", "values": [{"group": "Placebo", "value": 6.39}, {"group": "Eszopiclone", "value": 6.64}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=190,192)", "values": [{"group": "Placebo", "value": 6.17}, {"group": "Eszopiclone", "value": 6.6}]}, {"label": "Week 12 (n=190,192)", "values": [{"group": "Placebo", "value": 6.33}, {"group": "Eszopiclone", "value": 6.77}]}, {"label": "Week 0 (n=192,193)", "values": [{"group": "Placebo", "value": 5.66}, {"group": "Eszopiclone", "value": 5.63}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Physical Well-Being Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Subject-reported Physical Well-Being Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 0.52}, {"group": "Eszopiclone", "value": 0.87}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-reported Physical Well-being at Various Study Time Points.", "data": [{"label": "Week 6 (n=189,192)", "values": [{"group": "Placebo", "value": 0.46}, {"group": "Eszopiclone", "value": 0.84}]}, {"label": "Week 16 (n=189,192)", "values": [{"group": "Placebo", "value": 0.64}, {"group": "Eszopiclone", "value": 0.8}]}, {"label": "Week 3 (n=189,191)", "values": [{"group": "Placebo", "value": 0.35}, {"group": "Eszopiclone", "value": 0.68}]}, {"label": "Week 14 (n=189,192)", "values": [{"group": "Placebo", "value": 0.72}, {"group": "Eszopiclone", "value": 0.89}]}, {"label": "Week 9 (n=189,192)", "values": [{"group": "Placebo", "value": 0.61}, {"group": "Eszopiclone", "value": 0.93}]}, {"label": "Week 12 (n=189,192)", "values": [{"group": "Placebo", "value": 0.65}, {"group": "Eszopiclone", "value": 1.02}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-reported Physical Well-Being at Various Study Time Points", "data": [{"label": "Week 3 (n=190,191)", "values": [{"group": "Placebo", "value": 5.8}, {"group": "Eszopiclone", "value": 6.3}]}, {"label": "Week 16 (n=190,192)", "values": [{"group": "Placebo", "value": 6.09}, {"group": "Eszopiclone", "value": 6.43}]}, {"label": "Week 6 (n=190,192)", "values": [{"group": "Placebo", "value": 5.92}, {"group": "Eszopiclone", "value": 6.46}]}, {"label": "Week 9 (n=190,192)", "values": [{"group": "Placebo", "value": 6.06}, {"group": "Eszopiclone", "value": 6.56}]}, {"label": "Week 14 (n=190,192)", "values": [{"group": "Placebo", "value": 6.18}, {"group": "Eszopiclone", "value": 6.51}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=190,192)", "values": [{"group": "Placebo", "value": 5.97}, {"group": "Eszopiclone", "value": 6.49}]}, {"label": "Week 12 (n=190,192)", "values": [{"group": "Placebo", "value": 6.11}, {"group": "Eszopiclone", "value": 6.65}]}, {"label": "Week 0 (n=192,193)", "values": [{"group": "Placebo", "value": 5.45}, {"group": "Eszopiclone", "value": 5.62}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Counts of Number of Naps Per Week Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Subject-Reported Counts of Number of Naps Per Week Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": -0.78}, {"group": "Eszopiclone", "value": -1.23}]}], "yAxis": {"label": "Value", "unit": "number of naps"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline In Subject-Reported Counts of Number of Naps Per Week at Various Study Time Points", "data": [{"label": "Week 14 (n=110,93)", "values": [{"group": "Placebo", "value": -0.71}, {"group": "Eszopiclone", "value": -1.0}]}, {"label": "Week 16 (n=110,93)", "values": [{"group": "Placebo", "value": -0.92}, {"group": "Eszopiclone", "value": -1.29}]}, {"label": "Week 9 (n=110, 93)", "values": [{"group": "Placebo", "value": -0.96}, {"group": "Eszopiclone", "value": -1.33}]}, {"label": "Week 3 (n=110,92)", "values": [{"group": "Placebo", "value": -0.39}, {"group": "Eszopiclone", "value": -1.15}]}, {"label": "Week 6 (n=110,93)", "values": [{"group": "Placebo", "value": -0.8}, {"group": "Eszopiclone", "value": -1.26}]}, {"label": "Week 12 (n=110, 93)", "values": [{"group": "Placebo", "value": -0.96}, {"group": "Eszopiclone", "value": -1.18}]}], "yAxis": {"label": "Value", "unit": "number of naps"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-Reported Number of Naps Each Week at Various Study Time Points.", "data": [{"label": "Week 14 (n=110,93)", "values": [{"group": "Placebo", "value": 3.35}, {"group": "Eszopiclone", "value": 2.9}]}, {"label": "Week 0 (n=111,94)", "values": [{"group": "Placebo", "value": 4.03}, {"group": "Eszopiclone", "value": 3.88}]}, {"label": "Week 12 (n=110,93)", "values": [{"group": "Placebo", "value": 3.1}, {"group": "Eszopiclone", "value": 2.71}]}, {"label": "Week 16 (n=110,93)", "values": [{"group": "Placebo", "value": 3.14}, {"group": "Eszopiclone", "value": 2.61}]}, {"label": "Week 3 (n=110,92)", "values": [{"group": "Placebo", "value": 3.67}, {"group": "Eszopiclone", "value": 2.76}]}, {"label": "Week 6 (n=110,93)", "values": [{"group": "Placebo", "value": 3.26}, {"group": "Eszopiclone", "value": 2.64}]}, {"label": "Week 9 (n=110,93)", "values": [{"group": "Placebo", "value": 3.1}, {"group": "Eszopiclone", "value": 2.57}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=110,93)", "values": [{"group": "Placebo", "value": 3.28}, {"group": "Eszopiclone", "value": 2.66}]}], "yAxis": {"label": "Value", "unit": "number of naps"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change in Subject-Reported Total Nap Time Per Week Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change in Subject-Reported Total Nap Time Per Week Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": -36.02}, {"group": "Eszopiclone", "value": -60.06}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Total Nap Time Per Week at Various Study Time Points.", "data": [{"label": "Week 14 (n=110,93)", "values": [{"group": "Placebo", "value": -27.28}, {"group": "Eszopiclone", "value": -44.48}]}, {"label": "Week 12 (n=110,93)", "values": [{"group": "Placebo", "value": -42.15}, {"group": "Eszopiclone", "value": -58.22}]}, {"label": "Week 16 (n=110,93)", "values": [{"group": "Placebo", "value": -38.14}, {"group": "Eszopiclone", "value": -49.15}]}, {"label": "Week 3 (n=110,92)", "values": [{"group": "Placebo", "value": -21.66}, {"group": "Eszopiclone", "value": -59.06}]}, {"label": "Week 6 (n=110,93)", "values": [{"group": "Placebo", "value": -40.02}, {"group": "Eszopiclone", "value": -65.99}]}, {"label": "Week 9 (n=110,93)", "values": [{"group": "Placebo", "value": -40.25}, {"group": "Eszopiclone", "value": -56.59}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-Reported Total Nap Time at Various Study Time Points", "data": [{"label": "Week 14 (n=110,93)", "values": [{"group": "Placebo", "value": 163.61}, {"group": "Eszopiclone", "value": 128.5}]}, {"label": "Week 0 (n=111,94)", "values": [{"group": "Placebo", "value": 189.31}, {"group": "Eszopiclone", "value": 171.62}]}, {"label": "Week 12 (n=110,93)", "values": [{"group": "Placebo", "value": 148.75}, {"group": "Eszopiclone", "value": 114.76}]}, {"label": "Week 16 (n=110,93)", "values": [{"group": "Placebo", "value": 152.76}, {"group": "Eszopiclone", "value": 123.83}]}, {"label": "Week 3 (n=110,92)", "values": [{"group": "Placebo", "value": 169.24}, {"group": "Eszopiclone", "value": 114.43}]}, {"label": "Week 6 (n=110,93)", "values": [{"group": "Placebo", "value": 150.88}, {"group": "Eszopiclone", "value": 106.99}]}, {"label": "Week 9 (n=110,93)", "values": [{"group": "Placebo", "value": 150.65}, {"group": "Eszopiclone", "value": 116.39}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=110,93)", "values": [{"group": "Placebo", "value": 154.88}, {"group": "Eszopiclone", "value": 112.92}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Total Nap Time Per Week as a Percent of Total Asleep Time Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Subject-Reported Total Nap Time Per Week as a Percent of Total Asleep Time Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": -2.44}, {"group": "Eszopiclone", "value": -2.98}]}], "yAxis": {"label": "Value", "unit": "percentage of total asleep time"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Sleep Latency Values Measured Using Actigraphy at Various Study Time Points.", "data": [{"label": "Week 15 (n=68,67)", "values": [{"group": "Placebo", "value": 28.8}, {"group": "Eszopiclone", "value": 34.35}]}, {"label": "Week 1 (n=64,64)", "values": [{"group": "Placebo", "value": 37.74}, {"group": "Eszopiclone", "value": 26.72}]}, {"label": "Week 13 (n=68,67)", "values": [{"group": "Placebo", "value": 30.4}, {"group": "Eszopiclone", "value": 43.06}]}, {"label": "Week 0 (n=64,61)", "values": [{"group": "Placebo", "value": 31.34}, {"group": "Eszopiclone", "value": 23.89}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=68,67)", "values": [{"group": "Placebo", "value": 31.2}, {"group": "Eszopiclone", "value": 29.22}]}, {"label": "Week 12 (n=68,67)", "values": [{"group": "Placebo", "value": 27.89}, {"group": "Eszopiclone", "value": 36.93}]}, {"label": "Week 4 (n=67,67)", "values": [{"group": "Placebo", "value": 28.55}, {"group": "Eszopiclone", "value": 26.62}]}, {"label": "Week 7 (n=68,67)", "values": [{"group": "Placebo", "value": 31.06}, {"group": "Eszopiclone", "value": 26.89}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Subject-Reported Total Nap Time Stated as a Percentage of the Total Asleep Time at Various Study Time Points", "data": [{"label": "Week 14 (n=110,93)", "values": [{"group": "Placebo", "value": -2.31}, {"group": "Eszopiclone", "value": -2.14}]}, {"label": "Week 12 (n=110,93)", "values": [{"group": "Placebo", "value": -2.76}, {"group": "Eszopiclone", "value": -3.04}]}, {"label": "Week 16 (n=110,93)", "values": [{"group": "Placebo", "value": -2.55}, {"group": "Eszopiclone", "value": -2.38}]}, {"label": "Week 3 (n=110,92)", "values": [{"group": "Placebo", "value": -1.78}, {"group": "Eszopiclone", "value": -2.77}]}, {"label": "Week 6 (n=110,93)", "values": [{"group": "Placebo", "value": -2.52}, {"group": "Eszopiclone", "value": -3.16}]}, {"label": "Week 9 (n=110,93)", "values": [{"group": "Placebo", "value": -2.72}, {"group": "Eszopiclone", "value": -2.94}]}], "yAxis": {"label": "Value", "unit": "percentage of total asleep time"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Insomnia Severity Index Total Score at Various Study Time Points", "data": [{"label": "Week 14 (n=181,182)", "values": [{"group": "Placebo", "value": -3.93}, {"group": "Eszopiclone", "value": -4.06}]}, {"label": "Week 3 (n=179,181)", "values": [{"group": "Placebo", "value": -2.74}, {"group": "Eszopiclone", "value": -4.94}]}, {"label": "Week 9 (n=180,182)", "values": [{"group": "Placebo", "value": -3.55}, {"group": "Eszopiclone", "value": -5.89}]}, {"label": "Week 16 (n=181,182)", "values": [{"group": "Placebo", "value": -2.96}, {"group": "Eszopiclone", "value": -2.96}]}, {"label": "Week 12 (n=180,182)", "values": [{"group": "Placebo", "value": -4.05}, {"group": "Eszopiclone", "value": -6.18}]}, {"label": "Week 6 (n=180,181)", "values": [{"group": "Placebo", "value": -3.35}, {"group": "Eszopiclone", "value": -5.67}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Subject-Reported Total Nap Time Per Week Stated as a Percentage of the Total Asleep Time at Various Study Time Points", "data": [{"label": "Week 14 (n=110,93)", "values": [{"group": "Placebo", "value": 6.82}, {"group": "Eszopiclone", "value": 4.93}]}, {"label": "Week 0 (n=111,94)", "values": [{"group": "Placebo", "value": 9.05}, {"group": "Eszopiclone", "value": 7.02}]}, {"label": "Week 12 (n=110,93)", "values": [{"group": "Placebo", "value": 6.37}, {"group": "Eszopiclone", "value": 4.04}]}, {"label": "Week 16 (n=110,93)", "values": [{"group": "Placebo", "value": 6.57}, {"group": "Eszopiclone", "value": 4.69}]}, {"label": "Week 3 (n=110,92)", "values": [{"group": "Placebo", "value": 7.35}, {"group": "Eszopiclone", "value": 4.33}]}, {"label": "Week 6 (n=110,93)", "values": [{"group": "Placebo", "value": 6.61}, {"group": "Eszopiclone", "value": 3.91}]}, {"label": "Week 9 (n=110,93)", "values": [{"group": "Placebo", "value": 6.41}, {"group": "Eszopiclone", "value": 4.13}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=110,93)", "values": [{"group": "Placebo", "value": 6.68}, {"group": "Eszopiclone", "value": 4.09}]}], "yAxis": {"label": "Value", "unit": "percentage of total asleep time"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Sleep Time Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Total Sleep Time Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 14.4}, {"group": "Eszopiclone", "value": 17.96}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Sleep Time Measured by Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=61,61)", "values": [{"group": "Placebo", "value": 17.21}, {"group": "Eszopiclone", "value": 16.89}]}, {"label": "Week 12 (n=62,61)", "values": [{"group": "Placebo", "value": 18.93}, {"group": "Eszopiclone", "value": 18.08}]}, {"label": "Week 13 (n=62,61)", "values": [{"group": "Placebo", "value": 15.36}, {"group": "Eszopiclone", "value": -0.6}]}, {"label": "Week 1 (n=60,58)", "values": [{"group": "Placebo", "value": 3.72}, {"group": "Eszopiclone", "value": 14.97}]}, {"label": "Week 15 (n=62,61)", "values": [{"group": "Placebo", "value": 13.82}, {"group": "Eszopiclone", "value": 4.06}]}, {"label": "Week 7 (n=62,61)", "values": [{"group": "Placebo", "value": 15.72}, {"group": "Eszopiclone", "value": 22.12}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Total Sleep Time Measured by Actigraphy at Various Study Time Points", "data": [{"label": "Week 15 (n=68,67)", "values": [{"group": "Placebo", "value": 365.73}, {"group": "Eszopiclone", "value": 369.23}]}, {"label": "Week 1 (n=64,64)", "values": [{"group": "Placebo", "value": 354.11}, {"group": "Eszopiclone", "value": 381.52}]}, {"label": "Week 13 (n=68,67)", "values": [{"group": "Placebo", "value": 366.47}, {"group": "Eszopiclone", "value": 364.87}]}, {"label": "Week 0 (n=64,61)", "values": [{"group": "Placebo", "value": 351.06}, {"group": "Eszopiclone", "value": 367.95}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=68,67)", "values": [{"group": "Placebo", "value": 365.13}, {"group": "Eszopiclone", "value": 383.3}]}, {"label": "Week 12 (n=68,67)", "values": [{"group": "Placebo", "value": 368.7}, {"group": "Eszopiclone", "value": 382.04}]}, {"label": "Week 4 (n=67,67)", "values": [{"group": "Placebo", "value": 366.69}, {"group": "Eszopiclone", "value": 382.39}]}, {"label": "Week 7 (n=68,67)", "values": [{"group": "Placebo", "value": 368.58}, {"group": "Eszopiclone", "value": 386.96}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Sleep Latency Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Sleep Latency Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 0.0}, {"group": "Eszopiclone", "value": 1.47}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Sleep Latency Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=61,61)", "values": [{"group": "Placebo", "value": -2.16}, {"group": "Eszopiclone", "value": -1.48}]}, {"label": "Week 12 (n=62,61)", "values": [{"group": "Placebo", "value": -3.92}, {"group": "Eszopiclone", "value": 9.34}]}, {"label": "Week 13 (n=62,61)", "values": [{"group": "Placebo", "value": -0.69}, {"group": "Eszopiclone", "value": 16.13}]}, {"label": "Week 1 (n=60,58)", "values": [{"group": "Placebo", "value": 9.06}, {"group": "Eszopiclone", "value": -0.25}]}, {"label": "Week 15 (n=62,61)", "values": [{"group": "Placebo", "value": -3.66}, {"group": "Eszopiclone", "value": 6.44}]}, {"label": "Week 7 (n=62,61)", "values": [{"group": "Placebo", "value": 0.12}, {"group": "Eszopiclone", "value": -1.62}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Wake Time After Sleep Onset (WASO) Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Wake Time After Sleep Onset (WASO) Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 4.5}, {"group": "Eszopiclone", "value": -4.24}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=61,61)", "values": [{"group": "Placebo", "value": 4.67}, {"group": "Eszopiclone", "value": -3.88}]}, {"label": "Week 1 (n=59,58)", "values": [{"group": "Placebo", "value": 3.17}, {"group": "Eszopiclone", "value": -6.59}]}, {"label": "Week 12 (n=62,61)", "values": [{"group": "Placebo", "value": 3.24}, {"group": "Eszopiclone", "value": -2.54}]}, {"label": "Week 13 (n=62,61)", "values": [{"group": "Placebo", "value": 4.98}, {"group": "Eszopiclone", "value": 0.68}]}, {"label": "Week 15 (n=62,61)", "values": [{"group": "Placebo", "value": 7.74}, {"group": "Eszopiclone", "value": -0.27}]}, {"label": "Week 7 (n=62,61)", "values": [{"group": "Placebo", "value": 6.57}, {"group": "Eszopiclone", "value": -4.19}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Values for Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 15 (n=68,67)", "values": [{"group": "Placebo", "value": 67.07}, {"group": "Eszopiclone", "value": 62.27}]}, {"label": "Week 13 (n=68,67)", "values": [{"group": "Placebo", "value": 64.09}, {"group": "Eszopiclone", "value": 63.01}]}, {"label": "Week 0 (n=64,61)", "values": [{"group": "Placebo", "value": 60.27}, {"group": "Eszopiclone", "value": 63.75}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=68,67)", "values": [{"group": "Placebo", "value": 63.69}, {"group": "Eszopiclone", "value": 58.21}]}, {"label": "Week 12 (n=68,67)", "values": [{"group": "Placebo", "value": 62.41}, {"group": "Eszopiclone", "value": 60.22}]}, {"label": "Week 4 (n=67,67)", "values": [{"group": "Placebo", "value": 64.16}, {"group": "Eszopiclone", "value": 58.86}]}, {"label": "Week 7 (n=68,67)", "values": [{"group": "Placebo", "value": 65.81}, {"group": "Eszopiclone", "value": 58.09}]}, {"label": "Week 1 (n=63,64)", "values": [{"group": "Placebo", "value": 63.53}, {"group": "Eszopiclone", "value": 55.39}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points.", "data": [{"label": "Week 4 (n=57,58)", "values": [{"group": "Placebo", "value": 403.18}, {"group": "Eszopiclone", "value": 381.15}]}, {"label": "Week 1 (n=57,55)", "values": [{"group": "Placebo", "value": 399.19}, {"group": "Eszopiclone", "value": 445.84}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=58,58)", "values": [{"group": "Placebo", "value": 412.91}, {"group": "Eszopiclone", "value": 397.11}]}, {"label": "Week 13 (n=58,58)", "values": [{"group": "Placebo", "value": 456.48}, {"group": "Eszopiclone", "value": 350.52}]}, {"label": "Week 7 (n=58,58)", "values": [{"group": "Placebo", "value": 414.68}, {"group": "Eszopiclone", "value": 406.16}]}, {"label": "Week 15 (n=58,58)", "values": [{"group": "Placebo", "value": 452.93}, {"group": "Eszopiclone", "value": 436.03}]}, {"label": "Week 0 (n=62,58)", "values": [{"group": "Placebo", "value": 418.49}, {"group": "Eszopiclone", "value": 438.02}]}, {"label": "Week 12 (n=58,58)", "values": [{"group": "Placebo", "value": 430.5}, {"group": "Eszopiclone", "value": 364.34}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Number of Awakenings Using Actigraphy Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Number of Awakenings Using Actigraphy Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 0.87}, {"group": "Eszopiclone", "value": -0.18}]}], "yAxis": {"label": "Value", "unit": "number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in the Number of Awakenings Measured Using Actigraphy at Various Study Time Points.", "data": [{"label": "Week 4 (n=61,61)", "values": [{"group": "Placebo", "value": 0.79}, {"group": "Eszopiclone", "value": 0.04}]}, {"label": "Week 1 (n=59,58)", "values": [{"group": "Placebo", "value": 0.76}, {"group": "Eszopiclone", "value": -0.54}]}, {"label": "Week 12 (n=62,61)", "values": [{"group": "Placebo", "value": 0.95}, {"group": "Eszopiclone", "value": -0.1}]}, {"label": "Week 13 (n=62,61)", "values": [{"group": "Placebo", "value": 1.1}, {"group": "Eszopiclone", "value": 0.01}]}, {"label": "Week 15 (n=62,61)", "values": [{"group": "Placebo", "value": 1.36}, {"group": "Eszopiclone", "value": -0.13}]}, {"label": "Week 7 (n=62,61)", "values": [{"group": "Placebo", "value": 0.88}, {"group": "Eszopiclone", "value": -0.21}]}], "yAxis": {"label": "Value", "unit": "number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Number of Awakenings Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 15 (n=68,67)", "values": [{"group": "Placebo", "value": 22.87}, {"group": "Eszopiclone", "value": 22.38}]}, {"label": "Week 13 (n=68,67)", "values": [{"group": "Placebo", "value": 22.55}, {"group": "Eszopiclone", "value": 22.48}]}, {"label": "Week 0 (n=64,61)", "values": [{"group": "Placebo", "value": 21.49}, {"group": "Eszopiclone", "value": 22.84}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=68,67)", "values": [{"group": "Placebo", "value": 22.4}, {"group": "Eszopiclone", "value": 22.27}]}, {"label": "Week 12 (n=68,67)", "values": [{"group": "Placebo", "value": 22.36}, {"group": "Eszopiclone", "value": 22.37}]}, {"label": "Week 4 (n=67,67)", "values": [{"group": "Placebo", "value": 22.28}, {"group": "Eszopiclone", "value": 22.51}]}, {"label": "Week 7 (n=68,67)", "values": [{"group": "Placebo", "value": 22.52}, {"group": "Eszopiclone", "value": 22.19}]}, {"label": "Week 1 (n=63,64)", "values": [{"group": "Placebo", "value": 22.42}, {"group": "Eszopiclone", "value": 21.86}]}], "yAxis": {"label": "Value", "unit": "number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Number of Naps Per Week Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Number of Naps Per Week Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 1.61}, {"group": "Eszopiclone", "value": -2.67}]}], "yAxis": {"label": "Value", "unit": "number of naps"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in the Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=57,58)", "values": [{"group": "Placebo", "value": 1.02}, {"group": "Eszopiclone", "value": -3.43}]}, {"label": "Week 13 (n=58,58)", "values": [{"group": "Placebo", "value": 2.73}, {"group": "Eszopiclone", "value": -4.58}]}, {"label": "Week 1 (n=57,55)", "values": [{"group": "Placebo", "value": 1.33}, {"group": "Eszopiclone", "value": -0.62}]}, {"label": "Week 15 (n=58,58)", "values": [{"group": "Placebo", "value": 3.41}, {"group": "Eszopiclone", "value": -0.64}]}, {"label": "Week 7 (n=58,58)", "values": [{"group": "Placebo", "value": 1.68}, {"group": "Eszopiclone", "value": -2.83}]}, {"label": "Week 12 (n=58,58)", "values": [{"group": "Placebo", "value": 1.86}, {"group": "Eszopiclone", "value": -3.47}]}], "yAxis": {"label": "Value", "unit": "number of naps"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=57,58)", "values": [{"group": "Placebo", "value": 20.63}, {"group": "Eszopiclone", "value": 18.9}]}, {"label": "Week 1 (n=57,55)", "values": [{"group": "Placebo", "value": 20.94}, {"group": "Eszopiclone", "value": 21.69}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=58,58)", "values": [{"group": "Placebo", "value": 21.01}, {"group": "Eszopiclone", "value": 19.66}]}, {"label": "Week 13 (n=58,58)", "values": [{"group": "Placebo", "value": 22.12}, {"group": "Eszopiclone", "value": 17.75}]}, {"label": "Week 7 (n=58,58)", "values": [{"group": "Placebo", "value": 21.07}, {"group": "Eszopiclone", "value": 19.5}]}, {"label": "Week 15 (n=58,58)", "values": [{"group": "Placebo", "value": 22.8}, {"group": "Eszopiclone", "value": 21.69}]}, {"label": "Week 0 (n=62,58)", "values": [{"group": "Placebo", "value": 20.52}, {"group": "Eszopiclone", "value": 22.33}]}, {"label": "Week 12 (n=58,58)", "values": [{"group": "Placebo", "value": 21.25}, {"group": "Eszopiclone", "value": 18.86}]}], "yAxis": {"label": "Value", "unit": "number of naps"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline Total Nap Time Per Week Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline Total Nap Time Per Week Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": 21.26}, {"group": "Eszopiclone", "value": -40.91}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=57,58)", "values": [{"group": "Placebo", "value": 6.37}, {"group": "Eszopiclone", "value": -56.87}]}, {"label": "Week 13 (n=58,58)", "values": [{"group": "Placebo", "value": 64.84}, {"group": "Eszopiclone", "value": -87.5}]}, {"label": "Week 1 (n=57,55)", "values": [{"group": "Placebo", "value": 2.37}, {"group": "Eszopiclone", "value": 6.56}]}, {"label": "Week 15 (n=58,58)", "values": [{"group": "Placebo", "value": 61.28}, {"group": "Eszopiclone", "value": -1.99}]}, {"label": "Week 7 (n=58,58)", "values": [{"group": "Placebo", "value": 23.03}, {"group": "Eszopiclone", "value": -31.85}]}, {"label": "Week 12 (n=58,58)", "values": [{"group": "Placebo", "value": 38.86}, {"group": "Eszopiclone", "value": -73.67}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time Measured by Actigraphy and Averaged Over the 12 Week Double Blind Study Period.", "data": [{"label": "Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time Measured by Actigraphy and Averaged Over the 12 Week Double Blind Study Period.", "values": [{"group": "Placebo", "value": 0.45}, {"group": "Eszopiclone", "value": -1.75}]}], "yAxis": {"label": "Value", "unit": "percentage of total asleep time"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time as Measured by Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=57,58)", "values": [{"group": "Placebo", "value": -0.56}, {"group": "Eszopiclone", "value": -2.14}]}, {"label": "Week 13 (n=58,58)", "values": [{"group": "Placebo", "value": 0.94}, {"group": "Eszopiclone", "value": -2.63}]}, {"label": "Week 1 (n=57,55)", "values": [{"group": "Placebo", "value": 1.38}, {"group": "Eszopiclone", "value": -0.17}]}, {"label": "Week 15 (n=58,58)", "values": [{"group": "Placebo", "value": 0.95}, {"group": "Eszopiclone", "value": -0.04}]}, {"label": "Week 7 (n=58,58)", "values": [{"group": "Placebo", "value": 0.18}, {"group": "Eszopiclone", "value": -1.75}]}, {"label": "Week 12 (n=58,58)", "values": [{"group": "Placebo", "value": 0.46}, {"group": "Eszopiclone", "value": -2.7}]}], "yAxis": {"label": "Value", "unit": "percentage of total asleep time"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Total Nap Time Per Week as a Percentage of Total Asleep Time Measured Using Actigraphy at Various Study Time Points", "data": [{"label": "Week 4 (n=57,58)", "values": [{"group": "Placebo", "value": 14.35}, {"group": "Eszopiclone", "value": 11.92}]}, {"label": "Week 1 (n=57,55)", "values": [{"group": "Placebo", "value": 16.29}, {"group": "Eszopiclone", "value": 13.89}]}, {"label": "Weeks 1,4,7,12 (double blind average)(n=58,58)", "values": [{"group": "Placebo", "value": 15.16}, {"group": "Eszopiclone", "value": 12.3}]}, {"label": "Week 13 (n=58,58)", "values": [{"group": "Placebo", "value": 15.66}, {"group": "Eszopiclone", "value": 11.43}]}, {"label": "Week 7 (n=58,58)", "values": [{"group": "Placebo", "value": 14.9}, {"group": "Eszopiclone", "value": 12.3}]}, {"label": "Week 15 (n=58,58)", "values": [{"group": "Placebo", "value": 15.66}, {"group": "Eszopiclone", "value": 14.01}]}, {"label": "Week 0 (n=62,58)", "values": [{"group": "Placebo", "value": 15.12}, {"group": "Eszopiclone", "value": 14.05}]}, {"label": "Week 12 (n=58,58)", "values": [{"group": "Placebo", "value": 15.18}, {"group": "Eszopiclone", "value": 11.36}]}], "yAxis": {"label": "Value", "unit": "percentage of total asleep time"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Insomnia Severity Index Total Score Averaged Over the 12 Week Double Blind Study Period", "data": [{"label": "Mean Change From Baseline in Insomnia Severity Index Total Score Averaged Over the 12 Week Double Blind Study Period", "values": [{"group": "Placebo", "value": -3.42}, {"group": "Eszopiclone", "value": -5.67}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Insomnia Severity Index Total Scores at Various Study Time Points", "data": [{"label": "Week 12 (n=181,185)", "values": [{"group": "Placebo", "value": 12.16}, {"group": "Eszopiclone", "value": 9.84}]}, {"label": "Week 6 (n=181,184)", "values": [{"group": "Placebo", "value": 12.87}, {"group": "Eszopiclone", "value": 10.4}]}, {"label": "Week 0 (n=192,190)", "values": [{"group": "Placebo", "value": 16.34}, {"group": "Eszopiclone", "value": 16.12}]}, {"label": "Week 14 (n=182,185)", "values": [{"group": "Placebo", "value": 12.3}, {"group": "Eszopiclone", "value": 11.94}]}, {"label": "Weeks 3,6,9,12 (double blind average)(n=181,185)", "values": [{"group": "Placebo", "value": 12.8}, {"group": "Eszopiclone", "value": 10.36}]}, {"label": "Week 16 (n=182,185)", "values": [{"group": "Placebo", "value": 13.28}, {"group": "Eszopiclone", "value": 13.05}]}, {"label": "Week 3 (n=180,183)", "values": [{"group": "Placebo", "value": 13.52}, {"group": "Eszopiclone", "value": 11.09}]}, {"label": "Week 9 (n=181,185)", "values": [{"group": "Placebo", "value": 12.66}, {"group": "Eszopiclone", "value": 10.12}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Physical Component Summary of the Short Form-36 Scale", "data": [{"label": "Week 6 (n=164,165)", "values": [{"group": "Placebo", "value": 1.01}, {"group": "Eszopiclone", "value": 1.0}]}, {"label": "Week 12 (n=165,166)", "values": [{"group": "Placebo", "value": 1.38}, {"group": "Eszopiclone", "value": 1.01}]}, {"label": "Week 16 (n=166,166)", "values": [{"group": "Placebo", "value": 0.69}, {"group": "Eszopiclone", "value": 0.39}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Physical Component Summary of the Short Form-36 Scale Scores.", "data": [{"label": "Week 0 (n=192,190)", "values": [{"group": "Placebo", "value": 43.99}, {"group": "Eszopiclone", "value": 45.39}]}, {"label": "Week 16 (n=167,169)", "values": [{"group": "Placebo", "value": 44.7}, {"group": "Eszopiclone", "value": 45.51}]}, {"label": "Week 12 (n=166,169)", "values": [{"group": "Placebo", "value": 45.38}, {"group": "Eszopiclone", "value": 46.12}]}, {"label": "Week 6 (n=165,168)", "values": [{"group": "Placebo", "value": 45.06}, {"group": "Eszopiclone", "value": 46.08}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Mental Component Summary of the Short Form-36 Scale Scores", "data": [{"label": "Week 6 (n=164,165)", "values": [{"group": "Placebo", "value": -0.44}, {"group": "Eszopiclone", "value": 0.96}]}, {"label": "Week 12 (n=165,166)", "values": [{"group": "Placebo", "value": -0.94}, {"group": "Eszopiclone", "value": 0.83}]}, {"label": "Week 16 (n=166,166)", "values": [{"group": "Placebo", "value": -1.22}, {"group": "Eszopiclone", "value": 0.2}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Mental Component Summary of the Short Form-36 Scale Scores", "data": [{"label": "Week 0 (n=192,190)", "values": [{"group": "Placebo", "value": 49.69}, {"group": "Eszopiclone", "value": 49.29}]}, {"label": "Week 16 (n=167,169)", "values": [{"group": "Placebo", "value": 48.68}, {"group": "Eszopiclone", "value": 49.23}]}, {"label": "Week 12 (n=166,169)", "values": [{"group": "Placebo", "value": 48.98}, {"group": "Eszopiclone", "value": 49.86}]}, {"label": "Week 6 (n=165,168)", "values": [{"group": "Placebo", "value": 49.49}, {"group": "Eszopiclone", "value": 49.96}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in the Sheehan Disability Scale Total Score.", "data": [{"label": "Week 6 (n=164,165)", "values": [{"group": "Placebo", "value": -2.6}, {"group": "Eszopiclone", "value": -4.05}]}, {"label": "Week 12 (n=165,166)", "values": [{"group": "Placebo", "value": -3.73}, {"group": "Eszopiclone", "value": -4.48}]}, {"label": "Week 14 (n=166,166)", "values": [{"group": "Placebo", "value": -3.11}, {"group": "Eszopiclone", "value": -3.52}]}, {"label": "Week 16 (n=166,166)", "values": [{"group": "Placebo", "value": -3.33}, {"group": "Eszopiclone", "value": -2.47}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Sheehan Disability Total Scores", "data": [{"label": "Week 6 (n=165,168)", "values": [{"group": "Placebo", "value": 8.87}, {"group": "Eszopiclone", "value": 7.52}]}, {"label": "Week 12 (n=166,169)", "values": [{"group": "Placebo", "value": 7.7}, {"group": "Eszopiclone", "value": 7.08}]}, {"label": "Week 14 (n=166,166)", "values": [{"group": "Placebo", "value": 8.37}, {"group": "Eszopiclone", "value": 8.03}]}, {"label": "Week 16 (n=167,169)", "values": [{"group": "Placebo", "value": 8.12}, {"group": "Eszopiclone", "value": 9.06}]}, {"label": "Week 0 (n=192,190)", "values": [{"group": "Placebo", "value": 11.38}, {"group": "Eszopiclone", "value": 11.13}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Headache (20.65%), Dysgeusia (10.93%), Nasopharyngitis (9.31%).", "common": [{"event": "Headache", "percentage": 20.65}, {"event": "Dysgeusia", "percentage": 10.93}, {"event": "Nasopharyngitis", "percentage": 9.31}, {"event": "Back Pain", "percentage": 4.45}, {"event": "Dizziness", "percentage": 4.45}, {"event": "Diarrhoea", "percentage": 4.05}, {"event": "Cough", "percentage": 4.05}, {"event": "Stomach Discomfort", "percentage": 3.64}, {"event": "Influenza", "percentage": 3.64}, {"event": "Somnolence", "percentage": 3.64}, {"event": "Pharyngolaryngeal Pain", "percentage": 3.64}, {"event": "Dry Mouth", "percentage": 3.24}, {"event": "Fatigue", "percentage": 3.24}, {"event": "Nausea", "percentage": 2.83}, {"event": "Pain", "percentage": 2.83}, {"event": "Upper Respiratory Tract Infection", "percentage": 2.83}, {"event": "Myalgia", "percentage": 2.83}, {"event": "Anxiety", "percentage": 2.43}, {"event": "Rash", "percentage": 2.43}, {"event": "Arthralgia", "percentage": 2.02}, {"event": "Appendicitis Perforated", "percentage": 0.4}, {"event": "Cholecystisis", "percentage": 0.4}, {"event": "Pneumonia", "percentage": 0.4}, {"event": "Completed Suicide", "percentage": 0.4}, {"event": "Stress Urinary Incontinence", "percentage": 0.4}, {"event": "Rectocele", "percentage": 0.4}, {"event": "Arteriosclerosis", "percentage": 0.4}]}}, {"studyInfo": {"title": "Improving Sleep and Psychological Functioning in People With Depression and Insomnia", "institution": "Wake Forest University Health Sciences", "dates": {"start": null, "completion": "2008-12"}, "summary": null}, "participants": [{"groupName": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "dosage": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "medicationName": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "size": 20, "description": "Participants will receive treatment with eszopiclone and fluoxetine"}, {"groupName": "FLX Plus Placebo", "dosage": "FLX Plus Placebo", "medicationName": "FLX Plus Placebo", "size": 20, "description": "Participants will receive treatment with placebo and fluoxetine"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 40, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings", "data": [{"label": "Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings", "values": [{"group": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "value": 0.81}, {"group": "FLX Plus Placebo", "value": 1.2}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Relation to Self/Others (RSO) Basis-32 Subscale Ratings", "data": [{"label": "Relation to Self/Others (RSO) Basis-32 Subscale Ratings", "values": [{"group": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "value": 0.74}, {"group": "FLX Plus Placebo", "value": 1.04}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)", "data": [{"label": "Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)", "values": [{"group": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "value": 50.2}, {"group": "FLX Plus Placebo", "value": 46.9}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Insomnia Severity Index (ISI)", "data": [{"label": "Insomnia Severity Index (ISI)", "values": [{"group": "Fluoxetine (FLX) Plus Eszopiclone (ESZ)", "value": 21.1}, {"group": "FLX Plus Placebo", "value": 20.2}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "No adverse events reported.", "common": []}}, {"studyInfo": {"title": "A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)", "institution": "Eisai Inc.", "dates": {"start": null, "completion": "2010-05"}, "summary": null}, "participants": [{"groupName": "Eszopiclone 1 mg- Elderly", "dosage": "Eszopiclone 1 mg for 24 weeks", "medicationName": "Eszopiclone 1 mg", "size": 45, "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."}, {"groupName": "Eszopiclone 2 mg- Elderly", "dosage": "Eszopiclone 2 mg for 24 weeks", "medicationName": "Eszopiclone 2 mg", "size": 49, "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."}, {"groupName": "Eszopiclone 2 mg- Non-elderly", "dosage": "Eszopiclone 2 mg for 24 weeks", "medicationName": "Eszopiclone 2 mg", "size": 55, "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."}, {"groupName": "Eszopiclone 3 mg- Non-elderly", "dosage": "Eszopiclone 3 mg for 24 weeks", "medicationName": "Eszopiclone 3 mg", "size": 36, "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 185, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Mean Change From Baseline In Sleep Latency", "data": [{"label": "Overall Period (Change From Baseline)", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": -32.1}, {"group": "Eszopiclone 2 mg- Elderly", "value": -37.0}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": -36.7}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": -32.8}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": 65.5}, {"group": "Eszopiclone 2 mg- Elderly", "value": 70.7}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": 71.8}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": 64.0}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Incidence of Adverse Events", "data": [{"label": "Incidence of Adverse Events", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": 81.5}, {"group": "Eszopiclone 2 mg- Elderly", "value": 79.5}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": 82.1}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": 87.0}]}], "yAxis": {"label": "Value", "unit": "Percentage of Participants"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Wake Time After Sleep Onset (WASO)", "data": [{"label": "Overall Period (Change From Baseline)", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": -30.8}, {"group": "Eszopiclone 2 mg- Elderly", "value": -35.1}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": -32.4}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": -23.3}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": 61.6}, {"group": "Eszopiclone 2 mg- Elderly", "value": 68.8}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": 53.2}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": 42.3}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Sleep Time", "data": [{"label": "Overall Period (Change From Baseline)", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": 63.6}, {"group": "Eszopiclone 2 mg- Elderly", "value": 74.2}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": 70.2}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": 61.8}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": 314.2}, {"group": "Eszopiclone 2 mg- Elderly", "value": 307.9}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": 290.7}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": 308.2}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Change From Baseline in Total Number of Awakenings", "data": [{"label": "Overall Period (Change From Baseline)", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": -0.5}, {"group": "Eszopiclone 2 mg- Elderly", "value": -0.5}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": -0.7}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": -0.7}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 1 mg- Elderly", "value": 1.8}, {"group": "Eszopiclone 2 mg- Elderly", "value": 1.9}, {"group": "Eszopiclone 2 mg- Non-elderly", "value": 1.7}, {"group": "Eszopiclone 3 mg- Non-elderly", "value": 1.6}]}], "yAxis": {"label": "Value", "unit": "Number of Awakenings"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Dysgeusia (30.97%), Nasopharyngitis (17.85%), Somnolence (3.94%).", "common": [{"event": "Dysgeusia", "percentage": 30.97}, {"event": "Nasopharyngitis", "percentage": 17.85}, {"event": "Somnolence", "percentage": 3.94}, {"event": "Headache", "percentage": 3.41}, {"event": "Upper respiratory tract infection", "percentage": 3.41}, {"event": "Back pain", "percentage": 2.62}, {"event": "Blood creatine phosphokinase increased", "percentage": 2.62}, {"event": "Thirst", "percentage": 1.84}, {"event": "Pharyngitis", "percentage": 1.84}, {"event": "Gastritis", "percentage": 1.57}, {"event": "Stomatitis", "percentage": 1.57}, {"event": "White Blood Cell Count Increased", "percentage": 1.57}, {"event": "Glucose urine present", "percentage": 1.31}, {"event": "Dizziness", "percentage": 1.31}, {"event": "Malaise", "percentage": 1.31}, {"event": "Bronchitis", "percentage": 1.31}, {"event": "Contusion", "percentage": 1.31}, {"event": "Abdominal discomfort", "percentage": 1.05}, {"event": "Blood Urine Present", "percentage": 1.05}, {"event": "Hypertension", "percentage": 1.05}, {"event": "Anaemia", "percentage": 0.79}, {"event": "Cystitis", "percentage": 0.79}, {"event": "Influenza", "percentage": 0.79}, {"event": "Fall", "percentage": 0.79}, {"event": "Thermal Burn", "percentage": 0.79}, {"event": "Alanine Aminotransferase Increased", "percentage": 0.79}, {"event": "Gamma-glutamyltransferase Increased", "percentage": 0.79}, {"event": "Musculoskeletal Stiffness", "percentage": 0.79}, {"event": "Insomnia", "percentage": 0.79}, {"event": "Dermatitis Contact", "percentage": 0.79}, {"event": "Eczema", "percentage": 0.79}, {"event": "Abdominal Pain", "percentage": 0.52}, {"event": "Abdominal Pain Upper", "percentage": 0.52}, {"event": "Oral Discomfort", "percentage": 0.52}, {"event": "Reflux Oesophagitis", "percentage": 0.52}, {"event": "Hepatic Function Abnormal", "percentage": 0.52}, {"event": "Blood Triglycerides Increased", "percentage": 0.52}, {"event": "Eosinophil Count Increased", "percentage": 0.52}, {"event": "Myalgia", "percentage": 0.52}, {"event": "Musculoskeletal Pain", "percentage": 0.52}, {"event": "Sciatica", "percentage": 0.52}, {"event": "Appendicitis", "percentage": 0.26}, {"event": "Acute myocardial infarction", "percentage": 0.26}, {"event": "Clavicle fracture", "percentage": 0.26}, {"event": "Completed suicide", "percentage": 0.26}, {"event": "Type 1 diabetes mellitus", "percentage": 0.26}, {"event": "Major depressive disorder", "percentage": 0.26}, {"event": "Sick sinus syndrome", "percentage": 0.26}, {"event": "Loss of consciousness", "percentage": 0.26}, {"event": "Oesophagitis haemorrhagic", "percentage": 0.26}, {"event": "Angina pectoris", "percentage": 0.26}, {"event": "Calculus ureteric", "percentage": 0.26}, {"event": "Heat illness", "percentage": 0.26}]}}, {"studyInfo": {"title": "Sleep Loss and Mechanisms of Impaired Glucose Metabolism", "institution": "Brigham and Women's Hospital", "dates": {"start": null, "completion": "2008-08"}, "summary": null}, "participants": [{"groupName": "Active", "dosage": "active medication administration nightly before bed", "medicationName": "advil", "size": 2, "description": "Total of 10 participants enrolled"}, {"groupName": "Placebo", "dosage": "nightly administration of placebo before bed", "medicationName": "placebo", "size": 7, "description": "Total of 10 participants enrolled"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 20, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Post-treatment Leptin Levels", "data": [{"label": "Post-treatment Leptin Levels", "values": [{"group": "Active", "value": 5.49}, {"group": "Placebo", "value": 15.28}]}], "yAxis": {"label": "Value", "unit": "ng/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Pre-treatment Ghrelin Levels", "data": [{"label": "Pre-treatment Ghrelin Levels", "values": [{"group": "Active", "value": 573.14}, {"group": "Placebo", "value": 648.41}]}], "yAxis": {"label": "Value", "unit": "ng/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Post-treatment Ghrelin Levels", "data": [{"label": "Post-treatment Ghrelin Levels", "values": [{"group": "Active", "value": 544.95}, {"group": "Placebo", "value": 670.94}]}], "yAxis": {"label": "Value", "unit": "ng/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)", "data": [{"label": "Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)", "values": [{"group": "Active", "value": 0.53}, {"group": "Placebo", "value": 0.38}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Mean Lapses of Attention", "data": [{"label": "Change in Mean Lapses of Attention", "values": [{"group": "Active", "value": -0.04}, {"group": "Placebo", "value": 0.07}]}], "yAxis": {"label": "Value", "unit": "lapses of attention"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test", "data": [{"label": "Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test", "values": [{"group": "Active", "value": 0.33}, {"group": "Placebo", "value": -0.1}]}], "yAxis": {"label": "Value", "unit": "%/min, slope of natural log glucose"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Acute Insulin Response to Glucose (AIRg)", "data": [{"label": "Acute Insulin Response to Glucose (AIRg)", "values": [{"group": "Active", "value": 94.0}, {"group": "Placebo", "value": 25.1}]}], "yAxis": {"label": "Value", "unit": "mU*l^-1*min"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Insulin Sensitivity (SI)", "data": [{"label": "Change in Insulin Sensitivity (SI)", "values": [{"group": "Active", "value": -1.19}, {"group": "Placebo", "value": 0.05}]}], "yAxis": {"label": "Value", "unit": "mU/l)^-1*min^-1"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Glucose Effectiveness (SG)", "data": [{"label": "Change in Glucose Effectiveness (SG)", "values": [{"group": "Active", "value": 0.001}, {"group": "Placebo", "value": 0.001}]}], "yAxis": {"label": "Value", "unit": "min^-1"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in HbA1c Levels", "data": [{"label": "Change in HbA1c Levels", "values": [{"group": "Active", "value": 0.03}, {"group": "Placebo", "value": -0.09}]}], "yAxis": {"label": "Value", "unit": "percentage of glycosylation"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Pre-Treatment Leptin Levels", "data": [{"label": "Pre-Treatment Leptin Levels", "values": [{"group": "Active", "value": 4.99}, {"group": "Placebo", "value": 16.53}]}], "yAxis": {"label": "Value", "unit": "ng/mL"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Total Sleep Time as Reported in Sleep Diaries", "data": [{"label": "Change in Total Sleep Time as Reported in Sleep Diaries", "values": [{"group": "Active", "value": 0.58}, {"group": "Placebo", "value": 0.09}]}], "yAxis": {"label": "Value", "unit": "hours"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Total Sleep Time Measured by PSG", "data": [{"label": "Change in Total Sleep Time Measured by PSG", "values": [{"group": "Active", "value": 2.9}, {"group": "Placebo", "value": -6.4}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Feeling Hot (12.5%), Headache (8.75%), Unpleasant Taste (7.5%).", "common": [{"event": "Feeling Hot", "percentage": 12.5}, {"event": "Headache", "percentage": 8.75}, {"event": "Unpleasant Taste", "percentage": 7.5}, {"event": "Dizziness", "percentage": 6.25}, {"event": "Puncture Site Pain", "percentage": 6.25}, {"event": "Rash", "percentage": 5.0}, {"event": "Respiratory tract infection", "percentage": 5.0}, {"event": "Pain in extremity", "percentage": 5.0}, {"event": "Paraesthesia", "percentage": 5.0}, {"event": "Somnolence", "percentage": 5.0}, {"event": "Venipuncture site bruising", "percentage": 5.0}, {"event": "Abdominal Discomfort", "percentage": 3.75}, {"event": "Back Pain", "percentage": 2.5}, {"event": "Decreased appetite", "percentage": 2.5}, {"event": "Dry Mouth", "percentage": 2.5}, {"event": "Musculoskeletal pain", "percentage": 2.5}, {"event": "Burning at infusion site", "percentage": 1.25}, {"event": "Burning sensation", "percentage": 1.25}, {"event": "Constipation", "percentage": 1.25}, {"event": "Eye irritation", "percentage": 1.25}, {"event": "Injection pressure sensation", "percentage": 1.25}, {"event": "Laceration", "percentage": 1.25}, {"event": "Menstruation with increased bleeding", "percentage": 1.25}, {"event": "Nausea", "percentage": 1.25}, {"event": "Nervousness", "percentage": 1.25}, {"event": "Plantar fasciitis", "percentage": 1.25}, {"event": "Vasovagal reaction", "percentage": 1.25}, {"event": "Vasovagal syncope", "percentage": 1.25}]}}, {"studyInfo": {"title": "Treatment of Insomnia in Migraineurs", "institution": "MedVadis Research Corporation", "dates": {"start": null, "completion": "2008-09"}, "summary": null}, "participants": [{"groupName": "Eszopiclone 3 mg", "dosage": "3 mg Eszopiclone 6 weeks", "medicationName": "Eszopiclone 3 mg", "size": 29, "description": "Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. Treated for 6 weeks with 3mg eszopiclone, followed by a 2-week runout period. 5 visits: screening, randomization, compliance, end-treatment, exit/early termination."}, {"groupName": "Placebo", "dosage": "Placebo 6 weeks", "medicationName": "Placebo", "size": 34, "description": "Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. Treated for 6 weeks with placebo, followed by a 2-week runout period. 5 visits: screening, randomization, compliance, end-treatment, exit/early termination."}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 63, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Headache Intensity", "data": [{"label": "6 weeks", "values": [{"group": "Eszopiclone 3mg", "value": 5.5}, {"group": "Placebo", "value": 5.6}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 3mg", "value": 5.6}, {"group": "Placebo", "value": 5.3}]}], "yAxis": {"label": "Value", "unit": "score on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Quality of Sleep", "data": [{"label": "Daytime alertness, 6 weeks", "values": [{"group": "Placebo", "value": 6.6}, {"group": "Eszopiclone 3mg", "value": 6.9}]}, {"label": "Daytime alertness, Baseline", "values": [{"group": "Placebo", "value": 6.0}, {"group": "Eszopiclone 3mg", "value": 6.1}]}, {"label": "Daytime fatigue, 6 weeks", "values": [{"group": "Placebo", "value": 5.0}, {"group": "Eszopiclone 3mg", "value": 4.3}]}, {"label": "Overall sleep quality, Baseline", "values": [{"group": "Placebo", "value": 4.9}, {"group": "Eszopiclone 3mg", "value": 5.1}]}, {"label": "Daytime fatigue, Baseline", "values": [{"group": "Placebo", "value": 5.5}, {"group": "Eszopiclone 3mg", "value": 5.2}]}, {"label": "Daytime functioning, Baseline", "values": [{"group": "Placebo", "value": 6.3}, {"group": "Eszopiclone 3mg", "value": 6.5}]}, {"label": "Overall sleep quality, 6 weeks", "values": [{"group": "Placebo", "value": 6.2}, {"group": "Eszopiclone 3mg", "value": 6.7}]}, {"label": "Daytime functioning, 6 weeks", "values": [{"group": "Placebo", "value": 6.9}, {"group": "Eszopiclone 3mg", "value": 7.0}]}], "yAxis": {"label": "Value", "unit": "score on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Headache Duration", "data": [{"label": "6 weeks", "values": [{"group": "Placebo", "value": 3.8}, {"group": "Eszopiclone 3mg", "value": 3.9}]}, {"label": "Baseline", "values": [{"group": "Placebo", "value": 3.7}, {"group": "Eszopiclone 3mg", "value": 4.0}]}], "yAxis": {"label": "Value", "unit": "hours"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Total Sleep Time", "data": [{"label": "Baseline", "values": [{"group": "Eszopiclone 3mg", "value": 5.4}, {"group": "Placebo", "value": 5.5}]}, {"label": "6 week average", "values": [{"group": "Eszopiclone 3mg", "value": 6.3}, {"group": "Placebo", "value": 6.1}]}], "yAxis": {"label": "Value", "unit": "hours"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Nighttime Awakenings", "data": [{"label": "Nighttime Awakenings", "values": [{"group": "Eszopiclone 3mg", "value": 1.5}, {"group": "Placebo", "value": 2.1}]}, {"label": "6 weeks", "values": [{"group": "Eszopiclone 3mg", "value": 1.5}, {"group": "Placebo", "value": 2.2}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 3mg", "value": 2.4}, {"group": "Placebo", "value": 2.7}]}], "yAxis": {"label": "Value", "unit": "awakenings/night"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Daytime Fatigue", "data": [{"label": "Daytime Fatigue", "values": [{"group": "Eszopiclone 3mg", "value": 4.3}, {"group": "Placebo", "value": 4.8}]}], "yAxis": {"label": "Value", "unit": "score on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Headache Frequency", "data": [{"label": "6 weeks", "values": [{"group": "Eszopiclone 3mg", "value": 2.5}, {"group": "Placebo", "value": 2.5}]}, {"label": "Baseline", "values": [{"group": "Eszopiclone 3mg", "value": 2.9}, {"group": "Placebo", "value": 3.1}]}], "yAxis": {"label": "Value", "unit": "days/week"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "No adverse events reported.", "common": []}}, {"studyInfo": {"title": "Eszopiclone Treatment & Cortisol Responsivity", "institution": "Butler Hospital", "dates": {"start": null, "completion": "2009-08"}, "summary": null}, "participants": [{"groupName": "Open-label Eszopiclone", "dosage": "standard oral therapy for insomnia for 6 weeks", "medicationName": "eszopiclone", "size": 7, "description": "Standard dosing of drug for 6 weeks for insomnia"}], "outcomes": [{"metric_name": "Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug)", "data": [{"label": "Cortisol Response to the Dex/CRH Test Post-treatment (6 Weeks Oral Drug)", "values": [{"group": "Open-label Eszopiclone", "value": 108.98}]}], "yAxis": {"label": "Value", "unit": "nmol/L"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "No adverse events reported.", "common": []}}, {"studyInfo": {"title": "The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia", "institution": "Steward St. Elizabeth's Medical Center of Boston, Inc.", "dates": {"start": null, "completion": "2011-07"}, "summary": null}, "participants": [{"groupName": "Eszopiclone", "dosage": "Eszopiclone", "medicationName": "Eszopiclone", "size": 14, "description": "Lexapro for 10 weeks together with eszopiclone."}, {"groupName": "Placebo", "dosage": "Placebo", "medicationName": "Placebo", "size": 5, "description": "Escitalopram with placebo"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 19, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Change in Anterior Cingulate Cortex Glutamine From Baseline to Week 1.", "data": [{"label": "Change in Anterior Cingulate Cortex Glutamine From Baseline to Week 1.", "values": [{"group": "Eszopiclone", "value": 0.00059}, {"group": "Placebo", "value": 0.00908}]}], "yAxis": {"label": "Value", "unit": "ratio (glutamine to creatine)"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Thalamic Glutamine From Baseline to Week 1", "data": [{"label": "Change in Thalamic Glutamine From Baseline to Week 1", "values": [{"group": "Eszopiclone", "value": -0.6639}, {"group": "Placebo", "value": -0.3551}]}], "yAxis": {"label": "Value", "unit": "ratio (glutamine to creatine)"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Anterior Cingulate Cortex Glutamate From Baseline to Week 1", "data": [{"label": "Change in Anterior Cingulate Cortex Glutamate From Baseline to Week 1", "values": [{"group": "Eszopiclone", "value": -0.0066}, {"group": "Placebo", "value": 0.215}]}], "yAxis": {"label": "Value", "unit": "ratio (glutamate to creatine)"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Thalamic Glutamate From Baseline to Week 1", "data": [{"label": "Change in Thalamic Glutamate From Baseline to Week 1", "values": [{"group": "Eszopiclone", "value": -0.0016}, {"group": "Placebo", "value": -0.7715}]}], "yAxis": {"label": "Value", "unit": "ratio (glutamate to creatine)"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Anterior Cingulate Cortex GABA From Baseline to Week 1", "data": [{"label": "Change in Anterior Cingulate Cortex GABA From Baseline to Week 1", "values": [{"group": "Eszopiclone", "value": 0.0013}, {"group": "Placebo", "value": -0.0036}]}], "yAxis": {"label": "Value", "unit": "ratio (GABA to creatine)"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Thalamic GABA From Baseline to Week 1", "data": [{"label": "Change in Thalamic GABA From Baseline to Week 1", "values": [{"group": "Eszopiclone", "value": -0.0002}, {"group": "Placebo", "value": -0.0058}]}], "yAxis": {"label": "Value", "unit": "ratio (GABA to creatine)"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Hamilton Depression Rating Scale Score From Baseline to Week 10", "data": [{"label": "Change in Hamilton Depression Rating Scale Score From Baseline to Week 10", "values": [{"group": "Eszopiclone", "value": -13.4}, {"group": "Placebo", "value": -20.75}]}], "yAxis": {"label": "Value", "unit": "scores on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Hamilton Anxiety Rating Scale Score From Baseline to Week 10", "data": [{"label": "Change in Hamilton Anxiety Rating Scale Score From Baseline to Week 10", "values": [{"group": "Eszopiclone", "value": -11.4}, {"group": "Placebo", "value": -12.0}]}], "yAxis": {"label": "Value", "unit": "scores on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Change in Insomnia Severity Index Score From Baseline to Week 10", "data": [{"label": "Change in Insomnia Severity Index Score From Baseline to Week 10", "values": [{"group": "Eszopiclone", "value": -11.2}, {"group": "Placebo", "value": -9.5}]}], "yAxis": {"label": "Value", "unit": "scores on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were somnolescence (50.0%), jaw pain (25.0%), MRI abnormality (25.0%).", "common": [{"event": "somnolescence", "percentage": 50.0}, {"event": "jaw pain", "percentage": 25.0}, {"event": "MRI abnormality", "percentage": 25.0}]}}, {"studyInfo": {"title": "Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study", "institution": "University of Minnesota", "dates": {"start": null, "completion": "2009-06"}, "summary": null}, "participants": [{"groupName": "Randomized to MBSR", "dosage": "", "medicationName": "", "size": 15, "description": "Total of all reporting groups"}, {"groupName": "Randomized to PCT", "dosage": "", "medicationName": "", "size": 7, "description": "Total of all reporting groups"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 22, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Pittsburgh Sleep Quality Index (PSQI)", "data": [{"label": "8 weeks", "values": [{"group": "MBSR", "value": 7.7}, {"group": "Pharmacotherapy Control Arm", "value": 9.2}]}, {"label": "5 months", "values": [{"group": "MBSR", "value": 7.0}, {"group": "Pharmacotherapy Control Arm", "value": 8.2}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Insomnia Severity Index", "data": [{"label": "5 months", "values": [{"group": "MBSR", "value": 8.1}, {"group": "Pharmacotherapy Control Arm", "value": 7.8}]}, {"label": "8 week", "values": [{"group": "MBSR", "value": 9.6}, {"group": "Pharmacotherapy Control Arm", "value": 9.1}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Actigraphy", "data": [{"label": "Actigraphy", "values": [{"group": "MBSR", "value": 6.2}, {"group": "Pharmacotherapy Control Arm", "value": 6.9}]}], "yAxis": {"label": "Value", "unit": "hours"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "State-Trait Anxiety Inventory (STAI)", "data": [{"label": "5 months", "values": [{"group": "MBSR", "value": 30.1}, {"group": "Pharmacotherapy Control Arm", "value": 28.3}]}, {"label": "8 week", "values": [{"group": "MBSR", "value": 32.9}, {"group": "Pharmacotherapy Control Arm", "value": 31.3}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Center for Epidemiological Studies Depression Scale (CES-D)", "data": [{"label": "5 months", "values": [{"group": "MBSR", "value": 8.4}, {"group": "Pharmacotherapy Control Arm", "value": 7.0}]}, {"label": "8 week", "values": [{"group": "MBSR", "value": 10.0}, {"group": "Pharmacotherapy Control Arm", "value": 10.1}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Medical Outcome Study Short Form (SF-12)", "data": [{"label": "5 months", "values": [{"group": "MBSR", "value": 49.7}, {"group": "Pharmacotherapy Control Arm", "value": 50.1}]}, {"label": "8 week", "values": [{"group": "MBSR", "value": 48.8}, {"group": "Pharmacotherapy Control Arm", "value": 48.3}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Taste disturbance (26.67%), Excessive sleepiness (20.0%), Headache (13.33%).", "common": [{"event": "Taste disturbance", "percentage": 26.67}, {"event": "Excessive sleepiness", "percentage": 20.0}, {"event": "Headache", "percentage": 13.33}, {"event": "Dizziness", "percentage": 13.33}, {"event": "Reflux", "percentage": 6.67}, {"event": "Anxiety", "percentage": 6.67}, {"event": "Hypertension", "percentage": 6.67}, {"event": "Strange dreams", "percentage": 6.67}]}}, {"studyInfo": {"title": "Treatment of Insomnia and Glucose Metabolism", "institution": "University of Chicago", "dates": {"start": null, "completion": "2012-03"}, "summary": null}, "participants": [{"groupName": "Eszopiclone or Placebo", "dosage": "Eszopiclone 3 mg daily at bedtime for 9 days", "medicationName": "Eszopiclone", "size": 14, "description": "Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded."}], "outcomes": [], "adverse_events": {"summary": "The most common side effects reported were Furuncle (100.0%).", "common": [{"event": "Furuncle", "percentage": 100.0}]}}, {"studyInfo": {"title": "Study of the Insomnia in Patients With Low Back Pain", "institution": "Duke University", "dates": {"start": null, "completion": "2010-09"}, "summary": null}, "participants": [{"groupName": "Eszopiclone", "dosage": "Eszopiclone 3 mg po nightly for duration of study blind phase", "medicationName": "Eszopiclone", "size": 20, "description": "Total of all reporting groups"}, {"groupName": "Placebo", "dosage": "Placebo nightly over duration of double blind study phase", "medicationName": "Placebo", "size": 18, "description": "Total of all reporting groups"}, {"groupName": "Total", "dosage": "", "medicationName": "", "size": 58, "description": "Total of all reporting groups"}], "outcomes": [{"metric_name": "Mean Subjective Sleep Diary Derived Total Sleep Time (TST)", "data": [{"label": "postnaprosyn baseline", "values": [{"group": "Eszopiclone", "value": 316.96}, {"group": "Placebo", "value": 380.45}]}, {"label": "week 2", "values": [{"group": "Eszopiclone", "value": 421.97}, {"group": "Placebo", "value": 382.11}]}, {"label": "week 1", "values": [{"group": "Eszopiclone", "value": 403.47}, {"group": "Placebo", "value": 375.56}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 411.97}, {"group": "Placebo", "value": 388.96}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Visual Analog Scale Pain Ratings (VAS)", "data": [{"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 34.7}, {"group": "Placebo", "value": 51.25}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 40.72}, {"group": "Placebo", "value": 51.99}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 31.69}, {"group": "Placebo", "value": 51.6}]}, {"label": "Postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 48.51}, {"group": "Placebo", "value": 53.79}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Mean Sleep Onset Latency (SOL)", "data": [{"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 17.5}, {"group": "Placebo", "value": 23.1}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 22.36}, {"group": "Placebo", "value": 27.0}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 15.28}, {"group": "Placebo", "value": 19.91}]}, {"label": "Postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 38.28}, {"group": "Placebo", "value": 34.11}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Wake Time After Sleep Onset", "data": [{"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 37.07}, {"group": "Placebo", "value": 81.32}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 49.34}, {"group": "Placebo", "value": 76.71}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 36.74}, {"group": "Placebo", "value": 76.18}]}, {"label": "Postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 91.51}, {"group": "Placebo", "value": 81.43}]}], "yAxis": {"label": "Value", "unit": "minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Number of Awakenings", "data": [{"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 1.35}, {"group": "Placebo", "value": 2.13}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 1.31}, {"group": "Placebo", "value": 1.98}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 1.33}, {"group": "Placebo", "value": 2.34}]}, {"label": "Postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 2.29}, {"group": "Placebo", "value": 2.08}]}], "yAxis": {"label": "Value", "unit": "awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Sleep Quality Ratings", "data": [{"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 6.18}, {"group": "Placebo", "value": 5.33}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 5.99}, {"group": "Placebo", "value": 4.9}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 6.38}, {"group": "Placebo", "value": 5.29}]}, {"label": "Postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 4.52}, {"group": "Placebo", "value": 4.44}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Insomnia Severity Index (ISI)", "data": [{"label": "Postnaprosyn baseline", "values": [{"group": "Eszopiclone", "value": 18.0}, {"group": "Placebo", "value": 16.78}]}, {"label": "Prenaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 18.85}, {"group": "Placebo", "value": 20.26}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 11.28}, {"group": "Placebo", "value": 12.85}]}, {"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 10.61}, {"group": "Placebo", "value": 12.74}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 8.38}, {"group": "Placebo", "value": 13.75}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Patient Global Impression of Pain Ratings", "data": [{"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 3.3}, {"group": "Placebo", "value": 4.01}]}, {"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 3.54}, {"group": "Placebo", "value": 3.82}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 3.08}, {"group": "Placebo", "value": 3.8}]}, {"label": "postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 4.02}, {"group": "Placebo", "value": 3.9}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Roland Morris Low Back Pain Inventory (RMLBPI)", "data": [{"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 9.1}, {"group": "Placebo", "value": 9.05}]}, {"label": "postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 9.97}, {"group": "Placebo", "value": 10.3}]}, {"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 7.63}, {"group": "Placebo", "value": 9.32}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 6.59}, {"group": "Placebo", "value": 7.94}]}, {"label": "prenaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 12.27}, {"group": "Placebo", "value": 11.33}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Hamilton Depression Rating Scale (HAM-D-24)", "data": [{"label": "Week 1", "values": [{"group": "Eszopiclone", "value": 4.54}, {"group": "Placebo", "value": 5.53}]}, {"label": "postnaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 6.38}, {"group": "Placebo", "value": 6.57}]}, {"label": "Week 2", "values": [{"group": "Eszopiclone", "value": 4.14}, {"group": "Placebo", "value": 5.07}]}, {"label": "Week 4", "values": [{"group": "Eszopiclone", "value": 2.62}, {"group": "Placebo", "value": 6.21}]}, {"label": "prenaprosyn Baseline", "values": [{"group": "Eszopiclone", "value": 6.45}, {"group": "Placebo", "value": 7.1}]}], "yAxis": {"label": "Value", "unit": "units on a scale"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "No adverse events reported.", "common": []}}, {"studyInfo": {"title": "A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)", "institution": "Eisai Inc.", "dates": {"start": null, "completion": "2010-05"}, "summary": null}, "participants": [{"groupName": "Group 1", "dosage": "Eszopiclone 3 mg", "medicationName": "Eszopiclone", "size": 7, "description": "ABECD group with 7 participants"}, {"groupName": "Group 2", "dosage": "Eszopiclone 2 mg", "medicationName": "Eszopiclone", "size": 7, "description": "BCADE group with 7 participants"}, {"groupName": "Group 3", "dosage": "Eszopiclone 1 mg", "medicationName": "Eszopiclone", "size": 7, "description": "CDBEA group with 7 participants"}, {"groupName": "Group 4", "dosage": "Placebo", "medicationName": "Placebo", "size": 8, "description": "DECAB group with 8 participants"}, {"groupName": "Group 5", "dosage": "Zolpidem Tartrate 10 mg", "medicationName": "Zolpidem Tartrate", "size": 7, "description": "EADBC group with 7 participants"}, {"groupName": "Group 6", "dosage": "Eszopiclone 2 mg", "medicationName": "Eszopiclone", "size": 8, "description": "DCEBA group with 8 participants"}, {"groupName": "Group 7", "dosage": "Zolpidem Tartrate 10 mg", "medicationName": "Zolpidem Tartrate", "size": 7, "description": "EDACB group with 7 participants"}, {"groupName": "Group 8", "dosage": "Eszopiclone 3 mg", "medicationName": "Eszopiclone", "size": 7, "description": "AEBDC group with 7 participants"}, {"groupName": "Group 9", "dosage": "Eszopiclone 1 mg", "medicationName": "Eszopiclone", "size": 7, "description": "BACED group with 7 participants"}, {"groupName": "Group 10", "dosage": "Eszopiclone 2 mg", "medicationName": "Eszopiclone", "size": 7, "description": "CBDAE group with 7 participants"}], "outcomes": [{"metric_name": "Latency To Persistent Sleep (LPS)", "data": [{"label": "Latency To Persistent Sleep (LPS)", "values": [{"group": "Placebo", "value": 37.5}, {"group": "Eszopiclone 1 mg", "value": 24.4}, {"group": "Eszopiclone 2 mg", "value": 20.9}, {"group": "Eszopiclone 3 mg", "value": 12.8}, {"group": "Zolpidem Tartrate 10 mg", "value": 14.3}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Total Sleep Time (Objective & Subjective)", "data": [{"label": "Objective Total Sleep Time", "values": [{"group": "Placebo", "value": 414.0}, {"group": "Eszopiclone 1 mg", "value": 438.3}, {"group": "Eszopiclone 2 mg", "value": 452.5}, {"group": "Eszopiclone 3 mg", "value": 453.4}, {"group": "Zolpidem Tartrate 10 mg", "value": 448.6}]}, {"label": "Subjective Total Sleep Time", "values": [{"group": "Placebo", "value": 360.0}, {"group": "Eszopiclone 1 mg", "value": 390.0}, {"group": "Eszopiclone 2 mg", "value": 397.5}, {"group": "Eszopiclone 3 mg", "value": 420.0}, {"group": "Zolpidem Tartrate 10 mg", "value": 411.3}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Sleep Efficiency", "data": [{"label": "Sleep Efficiency", "values": [{"group": "Eszopiclone 1 mg", "value": 91.3}, {"group": "Placebo", "value": 86.3}, {"group": "Eszopiclone 2 mg", "value": 94.3}, {"group": "Eszopiclone 3 mg", "value": 94.5}, {"group": "Zolpidem Tartrate 10 mg", "value": 93.5}]}], "yAxis": {"label": "Value", "unit": "Percentage of time asleep of 8 hours"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Wake Time After Sleep Onset (WASO)- Objective & Subjective", "data": [{"label": "Objective Wake Time After Sleep Onset", "values": [{"group": "Placebo", "value": 26.3}, {"group": "Eszopiclone 1 mg", "value": 22.5}, {"group": "Eszopiclone 2 mg", "value": 17.8}, {"group": "Eszopiclone 3 mg", "value": 18.8}, {"group": "Zolpidem Tartrate 10 mg", "value": 20.0}]}, {"label": "Subjective Wake Time After Sleep Onset", "values": [{"group": "Placebo", "value": 75.0}, {"group": "Eszopiclone 1 mg", "value": 60.0}, {"group": "Eszopiclone 2 mg", "value": 37.5}, {"group": "Eszopiclone 3 mg", "value": 40.0}, {"group": "Zolpidem Tartrate 10 mg", "value": 50.0}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Number of Awakenings (Objective & Subjective)", "data": [{"label": "Objective Number of Awakenings", "values": [{"group": "Placebo", "value": 4.0}, {"group": "Eszopiclone 1 mg", "value": 4.0}, {"group": "Eszopiclone 2 mg", "value": 3.5}, {"group": "Eszopiclone 3 mg", "value": 2.8}, {"group": "Zolpidem Tartrate 10 mg", "value": 3.5}]}, {"label": "Subjective Number of Awakenings", "values": [{"group": "Placebo", "value": 3.0}, {"group": "Eszopiclone 1 mg", "value": 3.0}, {"group": "Eszopiclone 2 mg", "value": 2.5}, {"group": "Eszopiclone 3 mg", "value": 2.0}, {"group": "Zolpidem Tartrate 10 mg", "value": 2.0}]}], "yAxis": {"label": "Value", "unit": "Number of awakenings"}, "xAxis": {"label": "Time Period"}}, {"metric_name": "Sleep Latency (SL)", "data": [{"label": "Sleep Latency (SL)", "values": [{"group": "Placebo", "value": 62.0}, {"group": "Eszopiclone 1 mg", "value": 45.5}, {"group": "Eszopiclone 2 mg", "value": 32.6}, {"group": "Eszopiclone 3 mg", "value": 28.4}, {"group": "Zolpidem Tartrate 10 mg", "value": 28.0}]}], "yAxis": {"label": "Value", "unit": "Minutes"}, "xAxis": {"label": "Time Period"}}], "adverse_events": {"summary": "The most common side effects reported were Dysgeusia (38.64%), Somnolence (29.55%), Dermatitis Contact (13.64%).", "common": [{"event": "Dysgeusia", "percentage": 38.64}, {"event": "Somnolence", "percentage": 29.55}, {"event": "Dermatitis Contact", "percentage": 13.64}, {"event": "Dizziness", "percentage": 11.36}, {"event": "Feeling Abnormal", "percentage": 6.82}]}}]